phosphonoacetic acid has been researched along with aspartic acid in 444 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 196 (44.14) | 18.7374 |
| 1990's | 187 (42.12) | 18.2507 |
| 2000's | 51 (11.49) | 29.6817 |
| 2010's | 9 (2.03) | 24.3611 |
| 2020's | 1 (0.23) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Allwell, NM; Hofmann, GE; Lennick, M; Zaug, A | 1 |
| Cooney, DA; Jayaram, HN | 1 |
| Goldin, A; Houchens, DP; Johnson, RK; Osieka, R | 1 |
| Chabner, BA; Cohen, MH; Erlichman, C; Hubbard, SM; Levine, AS; McAvoy, LM; Strong, JM; Wiernik, PH | 1 |
| Kantrowitz, ER; Lipscomb, WN | 1 |
| Allewell, NM; Knier, BL | 1 |
| Cooney, DA; Cubillan, J; Jayaram, HN; Karlowicz, MG; Roettger, M | 1 |
| Padgett, RA; Stark, GR; Wahl, GM | 1 |
| Cysyk, RL; Muggia, FM; Rozencweig, M; Von Hoff, DD | 1 |
| Friedman, J; Hall, SW; Loo, TL; Moore, EC | 1 |
| Handschumacher, RE; Moyer, JD | 1 |
| Branfman, AR; Cysyk, RL; Kinney, YE; Strong, JM | 1 |
| Denine, EP; Giles, HD; Harrison, SD | 1 |
| Cooney, DA; Jayaram, HN; Johnson, RK; Kariya, S; Vistica, DT | 1 |
| Johnson, RK; Stark, GR; Swyryd, EA | 1 |
| Branfman, AR; Bruni, RJ; Valia, KH | 1 |
| Kwong, LK; Tsuboi, KK | 1 |
| Coleman, PF; Padgett, RA; Stark, GR; Wahl, GM | 1 |
| Johnson, RK | 1 |
| Edmunds, NH; Kwong, LK; Tsuboi, KK | 1 |
| Goldin, A; Inouye, T; Johnson, RK; Stark, GR | 1 |
| Gorman, PA; Smith, KA; Stark, GR; Stark, MB | 1 |
| Jacks, T; Livanos, E; Livingstone, LR; Sprouse, J; Tlsty, TD; White, A | 1 |
| Bonatti, S; Nüsse, M; Ottaggio, L; Viaggi, S | 1 |
| Harstrick, A; Köhne-Wömpner, CH; Rustum, YM; Schmoll, HJ | 1 |
| Commane, M; McIntyre, P; Perry, ME; Rolfe, M; Stark, GR | 1 |
| Colofiore, JR; Koutcher, JA; Martin, DS; Nord, LD; Stolfi, RL | 1 |
| Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R | 1 |
| Burman, DL; Peterson, CB; Schachman, HK | 1 |
| Eisenberg, BL; Fowler, WC; Hoffman, JP | 1 |
| Brochon, JC; Fetler, L; Hervé, G; Ladjimi, MM; Tauc, P | 1 |
| Chan, TC; Kuczek, T | 1 |
| Bischoff, FZ; Strong, LC; Tainsky, MA; Wahl, GM; Yin, Y | 1 |
| Stenram, U | 1 |
| Banerjee, TK; DiFino, SM; Engstrom, PF; Flynn, PJ; Heim, WJ; O'Dwyer, PJ; Ozols, RF; Rosvold, E; Schilder, R; Walczak, J | 1 |
| Sanchez, J; Tlsty, TD; White, A | 1 |
| Kantrowitz, ER; Newton, CJ; Stevens, RC | 1 |
| Hiddemann, W; Köhne-Wömpner, CH; Rustum, Y; Schmoll, HJ | 1 |
| Kemeny, NE; Martin, DS | 2 |
| Botet, J; Conti, JA; Costa, P; Kemeny, N; Martin, D; McCulloch, W; Niedzwiecki, D; Seiter, K; Wiseberg, J | 1 |
| Nelson, J; Qureshi, IA; Vasudevan, S | 1 |
| Schachman, HK; Turnbull, JL; Waldrop, GL | 1 |
| Cleland, WW; O'Leary, MH; Parmentier, LE; Schachman, HK; Turnbull, JL; Waldrop, GL | 1 |
| Cleland, WW; Lee, S; O'Leary, MH; Parmentier, LE; Schachman, HK; Turnbull, JL; Waldrop, GL | 1 |
| Cleland, WW; O'Leary, MH; Parmentier, LE; Schachman, HK | 1 |
| Blank, EW; Ceriani, RL; Pant, KD; Santos, O | 1 |
| Davidson, K; Forseth, B; Scott, J; Von Hoff, DD; Waddelow, T; Wahl, G | 1 |
| Von Hoff, DD | 1 |
| Colofiore, J; Comis, RL; Hoffman, J; Hudes, GR; LaCreta, FP; Martin, DS; O'Dwyer, PJ; Ozols, RF; Walczak, J | 1 |
| Peterson, CB; Schachman, HK | 1 |
| Ardalan, B; Benedetto, P; Feun, L; Livingstone, A; Morrell, L; Reddy, R; Richman, S; Savaraj, N; Stridhar, K; Waldman, S | 1 |
| Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C | 1 |
| Cheson, BD | 1 |
| Kopnin, BP; Sokova, OI | 1 |
| Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S | 1 |
| Allegra, CJ | 1 |
| Bruckner, HW; Motwani, BT | 1 |
| Schachman, HK; Wente, SR | 1 |
| Kantrowitz, ER; Middleton, SA; Tauc, P; Vachette, P | 1 |
| Bach, A; Fleming, TR; Goodman, P; MacDonald, JS; Morrell, LM; Richman, SP | 1 |
| Haran, MS; Kinsella, AR | 1 |
| Baselga, J; Casper, ES; Magill, GB; Markman, M; Ranhosky, A; Smart, TB | 1 |
| O'Dwyer, PJ | 3 |
| Dembowski, NJ; Kantrowitz, ER; Newton, CJ | 1 |
| Hart, IR; Kalebic, T; McMillan, TJ; Stark, GR | 1 |
| Chan, WW; Hutchinson, DW; Laing, NM; Oberg, B | 1 |
| Kantrowitz, ER; Newton, CJ | 1 |
| Eisenstein, E; Markby, DW; Schachman, HK | 1 |
| Kantrowitz, ER; Stebbins, JW; Zhang, Y | 1 |
| Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE | 1 |
| Cunin, R; Hervé, G; Ladjimi, MM; Van Vliet, F; Xi, XG | 1 |
| Cunin, R; De Staercke, C; De Wannemaeker, B; Glansdorff, N; Hervé, G; Ladjimi, MM; Piérard, A; Van Vliet, F; Xi, XG | 1 |
| Tlsty, TD | 1 |
| Dutta, PL; Foye, WO | 1 |
| Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM | 1 |
| Boothman, DA; Briggle, TV; Greer, SB; Perez, LM; Santos, O | 1 |
| Martin, DS | 3 |
| Kemeny, NE; Martin, DS; Schneider, A | 1 |
| Brison, O; Legouy, E; Meinkoth, JL; Wahl, GM | 1 |
| Colofiore, J; Derby, S; Kemeny, N; Martin, DS; Salvia, B; Sawyer, RC; Schneider, A | 1 |
| Azou, Y; Laval, M; Miassod, R | 1 |
| Kantrowitz, ER; Xu, W | 1 |
| Abbondandolo, A; Bonatti, S; Menichini, P; Miele, M; Ottaggio, L | 1 |
| Giulotto, E; Groves, R; Rolfe, M; Saito, I; Stark, GR | 1 |
| Brison, O; Fossar, N; Legouy, E; Lhomond, G | 1 |
| Carl, PL; Goz, B; Tlsty, TD | 1 |
| Laurensse, E; Leyva, A; Peters, GJ; Pinedo, HM | 2 |
| Markby, DW; Newell, JO; Schachman, HK | 1 |
| Schachman, HK; Werner, WE | 1 |
| Cann, JR; Schachman, HK; Werner, WE | 1 |
| Corder, TS; Wild, JR | 1 |
| Lum, K; Margolin, BH; Tlsty, TD | 1 |
| Chan, TC; Howell, SB | 2 |
| Baillon, J; Belhadj, O; Ben Hamida, M; Bettaieb, A; Fries, J; Hervé, G; Madani, S | 1 |
| Azou, Y; Giorgi, D; Laval, M; Rosset, R | 1 |
| Chisena, CA; Cowan, KH; Cysyk, RL; Karle, JM | 1 |
| Bhaduri, A; Mukherjee, T; Ray, M | 1 |
| Abbondandolo, A; Agnese, C; Bonatti, S; Cavolina, P; De Ambrosis, A; Degan, P; Di Leonardo, A; Miele, M; Ottaggio, L; Randazzo, R | 1 |
| Cillo, C; Hill, RP; Ling, V | 1 |
| McCord, S; Otto, E; Tlsty, TD | 1 |
| Buroker, TR; Cullinan, SA; Everson, LK; Fleming, TR; Klaassen, DJ; Krook, JE; Laurie, JA; Mailliard, JA; Marschke, RF; Moertel, CG | 1 |
| Giulotto, E; Saito, I; Stark, GR | 1 |
| Kleanthous, C; Schachman, HK; Wemmer, DE | 1 |
| Cho, YJ; Honzatko, RB; Ke, HM; Lipscomb, WN | 1 |
| Cole, SC; Yon, RJ | 1 |
| Hsuanyu, YC; Wedler, FC | 1 |
| Hoover, TA; Wales, ME; Wild, JR | 1 |
| Grem, JL; King, SA; Leyland-Jones, B; O'Dwyer, PJ | 1 |
| Hoth, DF; King, SA; Leyland-Jones, B; O'Dwyer, PJ | 1 |
| Cassady, JM; Jacobsen, LB; Morré, DJ; Putnam, JE; Sawick, DP | 1 |
| Ardalan, B; Silberman, H; Singh, G | 1 |
| Fox, M; Kinsella, AR; Szallasi, A | 1 |
| Fox, M; Kinsella, AR | 1 |
| Leyland-Jones, B; O'Dwyer, PJ | 1 |
| Lahue, RS; Schachman, HK | 2 |
| Krause, KL; Lipscomb, WN; Volź, KW | 3 |
| Flint, A; Markby, DW; Robey, EA; Schachman, HK; Wente, SR; Yang, YR | 1 |
| Gouaux, JE; Krause, KL; Lipscomb, WN | 1 |
| Belkaïd, M; Denis, M; Hervé, G; Penverne, B | 1 |
| Cillo, C; Dick, JE; Hill, RP; Ling, V | 1 |
| Bhalla, K; Grant, S | 1 |
| Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH | 1 |
| Fournier, RE; Killary, AM; Meinkoth, J; Wahl, GM | 1 |
| Chan, TC; Cleary, S; Howell, SB; Markman, M | 2 |
| Harrison, SD; O'Dwyer, PJ; Trader, MW | 1 |
| Martin, DS; Sawyer, RC; Stolfi, RL | 1 |
| Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC | 1 |
| Giulotto, E; Knights, C; Stark, GR | 1 |
| Chan, TC; Howell, SB; King, ME; Taetle, R; Young, B | 1 |
| Martin, DS; Sawyer, RC; Stolfi, RL; Young, CW | 1 |
| Hervé, G; Jones, PT; Moody, MF; Tauc, P; Vachette, P | 1 |
| Cohen, RE; Foote, J; Schachman, HK | 1 |
| Foote, J; Schachman, HK | 1 |
| Cohen, RE; Schachman, HK | 1 |
| Akazawa, S; Ayusawa, D; Kumai, R; Seno, T; Shimizu, K; Yoshida, S | 1 |
| Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M | 1 |
| Buzdar, AU; Hortobagyi, GN; Mann, GB; Valdivieso, M; Yap, HY | 1 |
| Schachman, HK; Wacks, DB | 2 |
| Duś, D; Kafarski, P; Lejczak, B; Mastalerz, P; Radzikowski, C | 1 |
| Farrington, GK; Kumar, A; Wedler, FC | 1 |
| Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M | 1 |
| de Goeij, CC; Evers, SG; Sluyser, M | 1 |
| Seaver, SS; Stark, GR; Swyryd, EA | 1 |
| Hoogenraad, J; Stark, GR; Yoshida, T | 1 |
| Collins, KD; Stark, GR | 1 |
| Creech, RH; Ettinger, DS; Ferraro, JA; Ruckdeschel, JC; Tritchler, D; Vogl, SE; Woll, J | 1 |
| DeConti, RC; Earhart, RH; Ohnuma, T; Rubin, J | 1 |
| Cadman, E; Grant, S; Jakubowski, A; Rauscher, F | 1 |
| Anukarahanonta, T; Holstege, A; Keppler, DO | 1 |
| Anderson, LW; Cysyk, RL; Dietrick, DD; Karle, JM | 1 |
| Padgett, RA; Stark, GR; Vitto, L; Wahl, GM | 1 |
| Powis, G | 1 |
| Pawlicki, M; Zuchowska-Vogelgesang, B | 1 |
| Casper, ES; Martin, DS; Sawyer, RC; Spiegelman, S; Stolfi, RL; Young, CW | 1 |
| Benvenuto, JA; Hurlbert, RB; Loo, TL; Miller, AA; Moore, EC | 1 |
| Ehrlich, CE; Stehman, FB | 1 |
| Cocconi, G; Heuson, JC; Mouridsen, HT; Palshof, T; Paridaens, R; Rotmensz, N; Rozencweig, M; Sylvester, R; Van Oosterom, A | 1 |
| Bramwell, V; Cheix, F; Mouridsen, HT; Rozencweig, M; Somers, R; Thomas, D; Van Oosterom, A | 1 |
| Kleeberg, UR; Mulder, JH; Rozencweig, M; Rümke, P; Thomas, D | 1 |
| Ardalan, B; Browning, S; Carr, BI; Chan, C; Chang, FF; Green, L; Multhauf, P; Presant, CA; Staples, R; Thayer, W | 1 |
| Bedikian, AY | 1 |
| Doyle, JA; Moertel, CG; Perry, HO; Rubin, J | 1 |
| Kleeberg, UR; Voigt, H | 1 |
| Ardalan, B; Jamin, D; Jayaram, HN; Presant, CA | 1 |
| Coren, A; Glick, JH; Muggia, FM; O'Connell, MJ; Opfell, RW; Tsiatis, AA | 1 |
| Briggle, TV; Greer, S; Mekras, JA; Perez, LM | 1 |
| Ginger, CD; Hill, B; Kilsby, J; McIntosh, RT; Wrigglesworth, R | 1 |
| de Saint Vincent, BR; Delbrück, S; Eckhart, W; Meinkoth, J; Vitto, L; Wahl, G | 1 |
| Rubnitz, J; Vitto, L; Wahl, GM | 1 |
| Anderson, LW; Cysyk, RL; Karle, JM | 1 |
| Kvols, LK; Moertel, CG; O'Connell, MJ; Rubin, J; Schutt, AJ | 1 |
| Bartlett, PA; Stark, GR | 1 |
| Compton, JG; Flatgaard, JE; Schachman, HK; Vickers, LP; Wall, KA | 1 |
| Shapiro, WR; Young, DF | 1 |
| Anderson, LW; Cysyk, RL; Monks, A; Strong, J | 1 |
| Yon, RJ | 1 |
| Erlichman, C; Vidgen, D | 1 |
| Hahn, RG; Kvols, LK; Moertel, CG; O'Connell, MJ; Rubin, J; Schutt, AJ | 1 |
| Gertz, MA; Moertel, CG; O'Connell, MJ; Rubin, J; Schutt, AJ | 1 |
| Hines, LH; White, JC | 2 |
| Creech, RH; Earhart, R; Ettinger, DS; Tritchler, D | 1 |
| Beecham, J; Bundy, B; DiSaia, PJ; Muss, HB; Stehman, FB | 1 |
| Bojan, F; Fox, M; Kinsella, AR | 2 |
| Lankelma, J; Laurensse, E; Leyva, A; Peters, GJ; Pinedo, HM | 1 |
| Martin, DS; Sawyer, RC; Spiegelman, S; Stolfi, RL; Young, CW | 1 |
| Ardeshir, F; Brison, O; Giulotto, E; Liao, WS; Stark, GR; Zieg, J | 1 |
| Ardeshir, F; Clayton, CE; Giulotto, E; Stark, GR; Swyryd, EA; Zieg, J | 1 |
| Earhart, RH; Elson, PJ; Hahn, RG; Rosenthal, SN; Slayton, RE | 1 |
| Casper, ES; Kemeny, N; Martin, DS; Michaelson, RA; Young, CW | 1 |
| Bundy, B; Creasman, WT; Muss, HB; Slavik, M; Stehman, FB | 1 |
| Gerok, W; Holstege, A; Manglitz, D | 1 |
| Benjamin, RS; Bodey, GP; Kurzrock, R; Papdopoulos, N; Plager, C; Valdivieso, M; Yap, BS | 1 |
| Choy, YM; Fung, KP; Lee, CY; Leung, SW | 1 |
| Altman, RB; Ladner, JE; Lipscomb, WN | 1 |
| Chabner, BA; Donehower, RC; Liang, CM | 1 |
| Ardalan, B; Jayaram, HN; Johnson, RK | 1 |
| Baillon, J; Guichard, M; Hervé, G; Malaise, EP | 1 |
| Casper, ES; Martin, DS; Vale, K; Williams, LJ; Young, CW | 1 |
| Creagan, ET; Kovach, JS; O'Connell, MJ | 1 |
| Christopherson, RI; Duggleby, RG | 1 |
| Ardeshir, F; Brison, O; Stark, GR | 1 |
| Chabner, BA; Donehower, RC; Erlichman, C; Klecker, R; Speyer, JL | 1 |
| Honzatko, RB; Kalb, AJ; Ke, HM; Kitchell, JP; Ladner, JE; Ladner, RC; Lipscomb, WN; Volz, KW | 1 |
| Cadman, E; Grant, S; Rauscher, F | 1 |
| Johnson, RS; Schachman, HK | 1 |
| Howlett, GJ; Hu, CY; Schachman, HK | 1 |
| Ginsburg, A; Schachman, HK; Shrake, A | 1 |
| Allewell, NM; Lennick, M | 1 |
| Moertel, CG; O'Connell, MJ; Powis, G; Rubin, J | 1 |
| Branfman, AR; Chadwick, M; Liss, RH; MacGregor, JA; Silveira, DM; Yesair, DW | 1 |
| Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR | 1 |
| Henderson, JF; Hunting, D | 1 |
| Cooney, DA; Jayaram, HN; Kensler, TW | 1 |
| Burns, DL; Schachman, HK | 1 |
| Casper, ES; Gralla, RJ; Kemeny, N; Wiley, RG | 1 |
| Handschumacher, RE; Levy, EJ; Moyer, JD; Smith, PA | 1 |
| Branfman, AR; Bruni, RJ; Chadwick, M; Ervin, TJ; Kufe, DW; Meshad, MW; Schade, D; Weiss, GR | 1 |
| Gralla, RJ; Kelsen, DP; Natale, RB; Watson, RC; Yagoda, A | 1 |
| Moore, EC | 1 |
| Friedman, J; Loo, TL; Marti, JR; Moore, EC; Plunkett, W; Russ, J; Valdivieso, M | 1 |
| Davis, TE; Falkson, G; Keller, AM; Taylor, SG | 1 |
| Bramwell, V; Kenny, JB; Kleeberg, UR; Lankelma, J; Leyva, A; McVie, JG; Penders, PG; Pinedo, HM | 1 |
| Lankelma, J; Leyva, A; Penders, PG; Pinedo, HM | 1 |
| Botkin, CC; Lee, EC; Sieber, SM; Soong, P; Whang-Peng, J | 1 |
| Handschumacher, RE; Moyer, JD; Oliver, JT | 1 |
| Koch, MR; Lea, MA | 1 |
| Kufe, DW; Loh, E | 1 |
| Appel, H; Lankelma, J; Leyva, A; Pinedo, HM; Smith, P | 1 |
| Brinster, RL; Troike, DE | 1 |
| Ardalan, B; Cooney, DA; Glazer, RI; Jayaram, HN; Kensler, TW; Macdonald, JS; Van Pham, T | 1 |
| Friedman, J; Loo, TL; Marti, JR; Moore, EC; Stewart, D; Valdivieso, M | 1 |
| Chabner, BA; Erlichman, C; Strong, JM | 1 |
| Roboz, J; Rose, E; Suzuki, R | 1 |
| Branfman, AR; Bruni, RJ; Chadwick, M; Ervin, TJ; Merrill, YN; Strong, JM | 1 |
| Anderson, LW; Cysyk, RL; Erlichman, C; Karle, JM | 1 |
| Benjamin, RS; Bodey, GP; Burgess, MA; Friedman, J; Leavens, M; Loo, TL; Moore, EC; Stewart, DJ; Valdivieso, M; Wiseman, C | 1 |
| Erlichman, C | 1 |
| Abele, R; Muggia, FM; Piccart, M; Rozencweig, M; Von Hoff, DD | 1 |
| Ardalan, B; Chadwick, M; Choie, DD; Cooney, DA; Jayaram, HN; Kensler, TW; Liss, R; Morrison, W | 1 |
| Grindey, GB; Kinahan, JJ; Kowal, EP | 1 |
| Ardalan, B; Cooney, DA; Cysyk, RL; Han, N; Hankerson, JG; Harley, C; Jayaram, HN; Johnson, RK; Kensler, TW; Mutter, G; Reck, LJ | 1 |
| Cooney, DA; Kensler, TW; Reck, LJ | 1 |
| Casper, ES; Gralla, RJ; Natale, RB; Yagoda, A; Young, CW | 1 |
| Blough, HA; Moore, DK; Pimentel, DM; Wyde, PR | 1 |
| Schimke, RT; Sharma, RC | 1 |
| Allegra, CJ; Grogan, L; Sotos, GA | 1 |
| Creaven, PJ; Meropol, NJ; Petrelli, NJ | 1 |
| Abbondandolo, A; Bonatti, S; Bozzo, S; Miele, M; Moro, F; Ottaggio, L; Simili, M | 1 |
| Briot, A; Livanos, E; Poulose, B; Roelofs, H; Sage, M; Tlsty, TD; White, A | 1 |
| Greer, S; Marion, HS; Schwade, J | 1 |
| Fetler, L; Hervé, G; Moody, MF; Tauc, P; Vachette, P | 1 |
| Cao, S; Durrani, FA; Mayhew, EG; Peters, GJ; Rustum, YM; Van Laar, JA | 1 |
| Cavolina, P; Di Leonardo, A; Maddalena, A | 1 |
| Duquesnoy, RJ; Fung, JJ; Starzl, TE; Todo, S; Venkataramanan, R; Yao, GZ; Zeevi, A | 1 |
| Seitz, JF | 1 |
| Buyse, M; Le Bourgeois, JP; Lévy, E; Piedbois, P | 1 |
| Kantrowitz, ER; Keiser, RT; Tauc, P; Vachette, P | 1 |
| Huang, A; Jin, H; Wright, JA | 2 |
| Burns, CM; Chernov, MV; Ishizaka, Y; Stark, GR | 1 |
| Machover, D | 1 |
| Ardalan, B; Doroshow, JH; Fleming, TR; Holcombe, RF; Leichman, CG; Mangalik, A; Meyers, FJ; Muggia, FM; Tangen, CM; Weiss, GR | 1 |
| Green, F; Hoffman, JP; O'Dwyer, PJ; Redei, I; Scher, R; Weiner, LM | 1 |
| Almasan, A; Bertino, JR; Bradley, A; Kelly, RE; Lee, EY; Li, W; Wahl, GM; Yin, Y | 1 |
| Brennan, J; Hageboutros, A; Hudes, GR; LaCreta, FP; McAleer, C; Newman, EM; O'Dwyer, PJ; Ozols, RF; Rogatko, A | 1 |
| Giulotto, E; Mondello, C; Nuzzo, F; Rady, M; Riboni, R | 1 |
| Attolini, C; Bertoni, L; Giulotto, E; Mucciolo, E; Tessera, L | 1 |
| Moretti, A; Piras, A; Rainaldi, G; Vatteroni, L | 1 |
| Huang, A; Wright, JA | 1 |
| Livanos, EM; Tlsty, TD; White, AE | 1 |
| Baker, DP; DeSena, E; Kantrowitz, ER; Stebbins, JW | 1 |
| Atanasov, BP; Hervé, G; Ladjimi, MM; Spassov, VZ; Villoutreix, BO | 1 |
| Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Kerr, DJ; Oster, W; Steward, WP; Yosef, H | 1 |
| Briot, A; Hall, I; Jonczyk, P; Livanos, E; Poulose, B; Roelofs, H; Sage, M; Schaefer, D; Tlsty, TD; White, A | 1 |
| Allewell, NM; Bromberg, S; LiCata, VJ; Mallikarachchi, D | 1 |
| Heerschap, A; Hofs, HP; Kamm, VJ; Rietjens, IM; Rosenbusch, G; Vervoort, J; Wagener, DJ | 1 |
| Ding, R; Smulson, M | 1 |
| Lum, L; Schachman, HK; Waldrop, GL; Zhou, BB | 1 |
| Goz, B; Jeffs, L | 1 |
| Ardalan, B; Donofrio, K; Livingstone, AS; Markoe, A; Reddy, R; Richman, SP; Schwade, J; Ucar, A | 1 |
| Caligo, MA; Mariani, T; Piras, A; Rainaldi, G; Vatteroni, L | 1 |
| Cao, S; Rustum, YM; Spector, T | 1 |
| Stambrook, PJ; Wani, MA; Xu, X | 1 |
| Allegra, CJ; Drake, JC; Grem, JL; McAtee, N; Steinberg, S | 1 |
| Colofiore, JR; Martin, DS; Nord, LD; Sternberg, S; Stolfi, RL | 1 |
| Nelson, J; Qureshi, IA; Sarma, DS; Vasudevan, S | 1 |
| Haigh, JR; Houben, K; Howard, BD; Ramachandran, B; Rozenberg, YY; Varpetian, A | 1 |
| Bajaj, R; Hallam, S; Mao, X; Schwartz, EL; Wadler, S | 1 |
| Sharma, A; Straubinger, NL; Straubinger, RM | 1 |
| Allegra, CJ; Drake, JC; Grem, JL | 1 |
| Fogli, MJ; Powers, VM; Schachman, HK; Yang, YR | 1 |
| Barrett, JC; Jonczyk, P; Lum, K; Tlsty, TD; White, A | 1 |
| Alfieri, AA; Colofiore, JR; Devitt, ML; Koutcher, JA; Martin, DS; Nord, LD; Stolfi, RL | 1 |
| Azou, Y; Laval, M | 1 |
| Arbuck, SG; Balis, F; Chisena, T; Cysyk, R; Drake, J; Grem, JL; Hamilton, JM; McAtee, N; Murphy, RF; Steinberg, SM | 1 |
| Livanos, EM; Schaefer, DI; Tlsty, TD; White, AE | 1 |
| Ahlgren, JD; Anderson, N; Kemeny, N; Lokich, JJ | 1 |
| Hudes, GR; Kitson, J; Litwin, S; O'Dwyer, PJ; Walczak, J; Watts, P; Weiner, LM | 1 |
| Schachman, HK; Zhou, BB | 1 |
| Colofiore, J; Kemeny, N; Martin, D; Sawyer, R; Schneider, A; Seiter, K; Williams, L | 1 |
| Durrani, FA; Rustum, YM; van Laar, JA | 1 |
| Chisena, C; Cysyk, RL; Grubb, MF; Hyman, R; Zaharevitz, DW | 1 |
| Brennan, J; Colofiore, J; Green, F; Hageboutros, A; Hoffman, J; Hudes, GR; LaCreta, FP; Martin, DS; O'Dwyer, PJ; Ozols, RF | 1 |
| Asano, K; Kakizoe, T; Machida, T; Ochiya, T; Ohishi, Y; Sakamoto, H; Sasaki, H; Sugimura, T; Terada, M; Yoshida, T | 1 |
| Capizzi, RL; Fernandes, DJ; Wheeler, KT; Yang, JL | 1 |
| Clarkin, KC; Di Leonardo, A; Linke, SP; Tsou, A; Wahl, GM | 1 |
| Colofiore, JR; Martin, DS; Nord, LD; Stolfi, RL | 4 |
| Kasperrs, GJ; Kazemier, KM; Noordhuis, P; Peters, GJ | 1 |
| Chevrette, M; Speevak, MD | 1 |
| Huber, BE; Wei, K | 1 |
| Clarkin, KC; Huang, LC; Wahl, GM | 1 |
| Kinsella, A; Pickard, M | 1 |
| Glick, AB; Quan, W; Weinberg, WC; Wu, IH; Yuspa, SH | 1 |
| Chen, CY; Gilmer, TM; Hall, I; Kastan, MB; Lansing, TJ; Tlsty, TD | 1 |
| Cowan, KH; Gudas, JM; Li, T; Nguyen, H; Robey, R; Sadzewicz, L; Wosikowski, K | 1 |
| Gleissner, B; Haynes, H; Hilgenfeld, RU; Kaleya, R; Kreuser, ED; Rozenblit, A; Thiel, E; Wadler, S | 1 |
| Blomgren, H; Ragnhammar, P | 1 |
| Conner, EA; Wirth, PJ | 1 |
| Chernova, OB; Gilbert, C; Poupon, MF; Smith, KA; Stark, GR | 1 |
| Ballon, D; Koutcher, JA; Mahmood, U; Martin, DS; Matei, C; Street, JC | 1 |
| Baker, DP; Fetler, L; Kantrowitz, ER; Vachette, P | 1 |
| Aucoin, JM; Baker, DP; Kantrowitz, ER; Pishko, EJ | 1 |
| Agarwal, A; Agarwal, ML; Chernova, OB; Davidson, JN; Duncan, P; Groves, RP; Martínez, JL; Patterson, TE; Smith, KA; Stark, GR; Stark, MB; Trent, JM | 1 |
| Kinsella, AR; Pickard, M; Smith, D | 1 |
| Martin, DS; Schwartz, GK | 1 |
| Ardalan, B; Fleming, TR; Macdonald, JS; Martino, RL; Morrell, LM; Richman, SP | 1 |
| Harris, M | 1 |
| Brennan, J; Greene, F; Hageboutros, A; Hudes, GR; LaCreta, FP; O'Dwyer, PJ | 1 |
| Köhne, CH; Schmoll, HJ; Schöffski, P; Wilke, H | 1 |
| Alfieri, AA; Colofiore, JR; Koutcher, JA; Martin, DS; Netto, G; Nord, LD; Reuter, V; Sternberg, SS; Stolfi, RL | 1 |
| Agarwal, A; Agarwal, ML; Stark, GR; Taylor, WR; Wagner, EF; Wang, ZQ | 1 |
| Bastow, KF; Goz, B | 1 |
| Blough, HA; Grem, JL; Katsafanas, GC; Moss, B | 1 |
| Gioeli, D; Hall, IJ; Tlsty, TD; Weissman, BE | 1 |
| Burns, BP; Hazell, SL; Mendz, GL | 2 |
| Fan, H; Huang, A; Taylor, WR; Wright, JA | 1 |
| Berns, T; Harstrick, A; Hiddemann, W; Köhne, CH; Preusser, P; Schmoll, HJ; Seeber, S; Strumberg, D; Wilke, H | 1 |
| Agarwal, ML; Chernov, MV; Chernova, OB; Ishizaka, Y; Stark, GR | 1 |
| Aladjem, MI; Hope, TJ; Jaenisch, R; Klemm, M; Rodewald, LW; Spike, BT; Wahl, GM | 1 |
| Bokemeyer, C; Dörken, B; Harstrick, A; Hiddemann, W; Köhne, CH; Schmoll, HJ; Schöffski, P; Wilke, H | 1 |
| Almasan, A; Brody, LL; Paulson, TG; Wahl, GM | 1 |
| Ardalan, B; Franceschi, D; Jaime, M; Luis, R | 1 |
| Davidson, JN; Qiu, Y | 2 |
| Aks, C; Clark, J; DeMaria, D; Johnson, C; Langer, CJ; Leighton, J; Litwin, S; Reilly, DM; Ridge, JA; Sauter, E; Schaebler, D | 1 |
| Allewell, NM; Hariharan, M | 1 |
| Cory, AH; Cory, JG | 1 |
| Capizzi, RL; Case, L; Fernandes, DJ; Fleming, RA; Homesley, H; Loggie, BW; Morris, R; Muss, HB; Richards, F; Russell, GB; Smith, S | 1 |
| Hata, H; Niimura, M; Yano, A | 1 |
| Chen, CY; Faller, DV; Forman, LW; Liou, J | 1 |
| Beeche, M; Bodnar, AG; Chang, E; Chiu, CP; Frolkis, M; Jiang, XR; Jimenez, G; Kusler, B; Sage, M; Tlsty, TD; Wahl, GM | 1 |
| Agarwal, A; Agarwal, ML; Stacey, DW; Stark, GR; Taylor, WR | 1 |
| Dutrillaux, B; Muleris, M; Poupon, MF; Remvikos, Y; Soulie, P | 1 |
| Alber, T; Beernink, PT; Endrizzi, JA; Schachman, HK | 2 |
| Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW | 1 |
| Hatake, K; Ishizaka, Y; Onozuka, Y; Shimura, M; Takaku, F; Yamaguchi, T | 1 |
| Dutta, M; Kantrowitz, ER; Macol, C; Stec, B; Tsuruta, H | 1 |
| Evans, D; Guy, H; Hervé, G; Lux, M; Penverne, B; Rotgeri, A; Serre, V | 1 |
| Belt, RJ; Bready, B; Dakhil, SR; Goodwin, JW; Gray, R; Hoff, PM; McGarry, W; Pazdur, R; Royce, ME; Winn, R | 1 |
| Fontanier-Razzaq, NC; Hay, SM; Rees, WD | 1 |
| Glaser, SS; Madison, LL; Wales, ME; Wild, JR | 1 |
| Büchele, T; Dempke, W; Grothey, A; Schmoll, HJ | 1 |
| Jin, L; Kantrowitz, ER; Lipscomb, WN; Stec, B | 1 |
| Basnakian, AG; James, SJ; Melnyk, S; Miller, BJ; Pogribna, M; Pogribny, IP | 1 |
| Bertoni, L; Giulotto, E; Mondello, C; Mucciolo, E | 1 |
| Agapova, LS; Chumakov, PM; Kopnin, BP; Kopnin, PB; Tulina, NM; Turovets, NA | 1 |
| Heath, TD; Kim, JS | 1 |
| Lin, YH; Ravatn, R; Stollar, V; Yadav, P | 1 |
| Kantrowitz, ER; Sakash, JB | 1 |
| Hei, TK; Piao, CQ | 1 |
| Costa, S; Costanzo, G; Di Leonardo, A; Polizzi, D; Seidita, G | 1 |
| Di Leonardo, A; Faravelli, M; Giulotto, E; Mondello, C; Pipitone, L; Rollier, A | 1 |
| Arbuck, SG; Benson, AB; Haller, DG; Hines, JD; Manola, J; Mayer, RJ; O'Dwyer, PJ; Ryan, LM; Valone, FH; Wadler, S; Weiner, LM | 1 |
| Beernink, PT; Graf, R; King, DS; Schachman, HK; Shah, SS; Yang, YR | 1 |
| Dolzan, M; Edmonson, S; Giulotto, E; Mondello, C; Rebuzzini, P; Taccioli, GE | 1 |
| Fetler, L; Vachette, P | 2 |
| Brochon, JC; Cunin, R; Fetler, L; Hervé, G; Tauc, P | 1 |
| Amin, K; Brown, CS; Bruno, MS; Heath, TD; Ng, KY | 1 |
| Hall, EJ; Hei, TK; Piao, CQ; Willey, JC; Wu, LJ | 1 |
| Bigner, SH; Chen, S; Modrich, P | 1 |
| Allegra, CJ; Chabuk, C; Chen, AP; Grabenc, M; Grem, JL; Grollman, F; Hamilton, JM; Schuler, B; Takimoto, CH; Yee, LK | 1 |
| Collins, M; Graves, LM; Haystead, TA; Huang, M; Kozlowski, P; Wang, Y | 1 |
| Baker, DP; Fetler, L; Kantrowitz, ER; Macol, CP; Tauc, P; Vachette, P | 1 |
| Albor, A; El-Hizawi, S; Kulesz-Martin, M; Lagowski, JP | 1 |
| Del Rosso, M; Dini, G; Fanti, E; Funghini, S; Magnelli, L; Rifkin, DB; Witort, E | 1 |
| Subrata, S; Ying, H | 1 |
| Lemoine, FJ; Marriott, SJ | 1 |
| Chan, RS; Kantrowitz, ER; Macol, CP; Sakash, JB; Tsuruta, H; West, JM | 1 |
| Kisliakova, TV; Malashicheva, AB; Pospelov, VA; Savatier, P | 1 |
| Giulotto, E; Guasconi, V; Mondello, C; Nuzzo, F | 1 |
| Cunin, R; Khan, S; Maes, D; Van Boxstael, S | 1 |
| Baron, B; Bleiberg, H; Blijham, GH; Couvreur, ML; De Greve, J; Genicot, B; Jansen, RL; Kok, TC; Nortier, JW; Wagener, T; Wils, J | 1 |
| Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS | 1 |
| Aubenque, M; Gagnard, V; Le Mellay, V; Leydet, A; Montero, JL; Morère, A | 1 |
| Lehnert, S; Li, Y; Owusu, A | 1 |
| Abbruzzese, JL; Ardalan, B; Balcerzak, SP; Benedetti, JK; Goodwin, JW; Lenz, HJ; Macdonald, JS; Samlowski, WE; Whitehead, RP | 1 |
| Huang, J; Lipscomb, WN | 1 |
| Abbruzzese, JL; Ardalan, B; Balcerzak, SP; Benedetti, JK; Gaynor, ER; Macdonald, JS; Whitehead, RP; Williamson, S | 1 |
| Fornace, AJ; Hollander, MC; Patterson, AD; Philburn, RT; Wyatt, MA | 1 |
| Kantrowitz, ER; Pastra-Landis, SC; Stieglitz, KA; Tsuruta, H; Xia, J | 1 |
| Cordi, A; Hervé, G; Lequeux, T; Masson, S; Pfund, E; Pierre, A; Serre, V; Vazeux, M | 1 |
| Garcia, RA; Gonzalez, A; Hu, Z; Liu, L; Saydoff, JA; von Borstel, RW | 1 |
| Kemeny, NE; Leonard, GD | 1 |
| Blasco, M; Giulotto, E; Martinelli, P; Mondello, C; Rebuzzini, P | 1 |
| Cardia, JP; Eldo, J; Kantrowitz, ER; O'Day, EM; Tsuruta, H; Xia, J | 1 |
| Bellissent-Funel, MC; Hervé, G; Zanotti, JM | 1 |
| Beltinger, C; Buechele, B; Debatin, KM; Simmet, T; Unger, MM; Ushmorov, A; Wahl, J | 1 |
| Agarwal, MK; Agarwal, ML; Breit, SN; Hastak, K; Jackson, MW; Stark, GR | 1 |
| Eldo, J; Heng, S; Kantrowitz, ER | 1 |
| Beaudoin, B; Bray, K; Chen, G; Degenhardt, K; Jin, S; Karp, CM; Kongara, S; Mathew, R; White, E | 1 |
| Agarwal, MK; Agarwal, ML; Agrawal, S; Amin, AR; Hastak, K; Jackson, MW; Jacobberger, JW; Paul, RK; Sramkoski, RM; Stark, GR; Thakur, VS | 1 |
| Coudray, L; Kantrowitz, ER; Montchamp, JL | 1 |
| Coudray, L; Montchamp, JL; Pennebaker, AF | 1 |
| Cai, S; Du, J; Jiang, J; Liu, L; Liu, Q; Sung, KL; Yan, X; Yang, L; Yang, Y; Yu, S; Zhang, H | 1 |
| Agarwal, MK; Agarwal, ML; Gupta, K; Ruhul Amin, AR; Shin, DM; Thakur, VS; Wald, DN | 1 |
| Dewhirst, M; Huang, C; Li, C; Liu, F; Neill, D; Ouyang, R; Yan, B | 1 |
| Grande-García, A; Lallous, N; Ramón-Maiques, S; Ruiz-Ramos, A | 1 |
| Gandhi, V; Panandikar, A; Sen, S; Wang, J; Yin, H | 1 |
| Grande-García, A; Moreno-Morcillo, M; Ramón-Maiques, S; Ruiz-Ramos, A; Velázquez-Campoy, A | 1 |
| Peters, GJ | 1 |
| Homer, CR; Jatana, S; Kabi, A; Madajka, M; McDonald, C; Papay, F; Ponti, AK | 1 |
| Barahona, M; Hodges, M; Yaliraki, SN | 1 |
| Bach, C; Baumert, TF; Brino, L; Crouchet, E; El Saghire, H; Garcia, T; Heydmann, L; Kopp, A; Pale, P; Pessaux, P; Schuster, C; Sureau, C; Turon-Lagot, V; Verrier, ER; Weiss, A; Zeisel, MB | 1 |
30 review(s) available for phosphonoacetic acid and aspartic acid
| Article | Year |
|---|---|
m-AMSA and PALA: two new agents in cancer chemotherapy.
Topics: Aminoacridines; Animals; Antineoplastic Agents; Aspartic Acid; Cell Division; Kinetics; Neoplasms, Experimental; Organophosphorus Compounds; Phosphonoacetic Acid | 1979 |
Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Interferons; Leucovorin; Methotrexate; Phosphonoacetic Acid | 1992 |
Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials as Topic; Drug Administration Schedule; Drug Synergism; Fluorouracil; Forecasting; Humans; Phosphonoacetic Acid | 1992 |
Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Phosphonoacetic Acid; RNA, Neoplasm; Thymidylate Synthase; Uridine Triphosphate | 1992 |
New mechanisms of gene amplification in drug resistance (the episome model).
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); CHO Cells; Cricetinae; Dihydroorotase; DNA, Circular; DNA, Neoplasm; Drug Resistance; Electrophoresis, Gel, Pulsed-Field; Extrachromosomal Inheritance; Gene Amplification; Gene Expression Regulation, Neoplastic; Membrane Glycoproteins; Multienzyme Complexes; Neoplasms; Oncogenes; Phosphonoacetic Acid; Plasmids | 1991 |
Chemotherapy of advanced cancer of the colon and rectum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Methotrexate; Phosphonoacetic Acid; Rectal Neoplasms | 1991 |
The role of low-dose PALA in biochemical modulation.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Fluorouracil; Humans; Neoplasms; Neoplasms, Experimental; Phosphonoacetic Acid; Pyrimidines | 1990 |
Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
Topics: Antineoplastic Agents; Aspartic Acid; Drug Evaluation; Drug Resistance; Humans; Organophosphorus Compounds; Phosphonoacetic Acid | 1988 |
Role of thymidine in biochemical modulation: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cytarabine; Deoxycytidine Kinase; DNA Replication; DNA, Neoplasm; Drug Evaluation; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Interphase; Kinetics; Leukemia; Methotrexate; Mice; Neoplasms; Neoplasms, Experimental; Nucleic Acid Synthesis Inhibitors; Nucleotides; Phosphonoacetic Acid; RNA, Neoplasm; Species Specificity; Thymidine | 1987 |
Biochemical modulation: application of laboratory models to the clinic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation; Fluorouracil; Humans; Methotrexate; Neoplasms, Experimental; Organophosphorus Compounds; Phosphonoacetic Acid; Thymidine | 1986 |
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Topics: Animals; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid | 1985 |
Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.
Topics: Antineoplastic Agents; Aspartic Acid; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Fluorouracil; Gallium; Humans; Kidney Diseases; Kinetics; Liver Diseases; Metabolic Clearance Rate; Methotrexate; Phosphonoacetic Acid; Protein Binding; Tegafur | 1982 |
[New antineoplastic agents, their value and use].
Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interferons; Medroxyprogesterone; Medroxyprogesterone Acetate; Methyltestosterone; Neoplasms; Phosphonoacetic Acid; Razoxane; Tamoxifen; Teniposide; Vinca Alkaloids | 1982 |
Regional and systemic chemotherapy for advanced colorectal cancer. A review.
Topics: Antineoplastic Agents; Aspartic Acid; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Methotrexate; Phosphonoacetic Acid; Rectal Neoplasms; Tegafur | 1983 |
Design and use of potent, specific enzyme inhibitors.
Topics: Affinity Labels; Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Catalysis; Cell Survival; Cells, Cultured; Computers; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Phosphonoacetic Acid; Structure-Activity Relationship; Thermodynamics | 1983 |
Neurological complications of antineoplastic therapy.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspartic Acid; Cisplatin; Cytarabine; Fluorouracil; Humans; Methotrexate; Nervous System Diseases; Phosphonoacetic Acid; Thymidine; Vinblastine; Vincristine | 1984 |
Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neoplasms; DNA, Neoplasm; Fluorouracil; Humans; Idoxuridine; Immunologic Factors; Interferons; Leucovorin; Methotrexate; Mice; Phosphonoacetic Acid; RNA, Neoplasm; Uracil; Uridine; Zidovudine | 1994 |
Biochemical modulation as an approach to reversal of antimetabolite resistance.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Resistance, Multiple; Fluorouracil; Humans; Interferons; Methylthioinosine; Multicenter Studies as Topic; Phosphonoacetic Acid; Purines; Pyrimidines; Thymidylate Synthase; Tumor Cells, Cultured | 1994 |
Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neoplasms; Diarrhea; Digestive System; Drug Administration Schedule; Fluorouracil; Gastrointestinal Agents; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Leucovorin; Octreotide; Phosphonoacetic Acid; Prodrugs; Randomized Controlled Trials as Topic; Thymidylate Synthase; Topoisomerase I Inhibitors | 1995 |
Genomic integrity and the genetics of cancer.
Topics: Adenovirus E1A Proteins; Adenoviruses, Human; Antimetabolites; Apoptosis; Aspartic Acid; Cell Cycle; Cells, Cultured; Drug Resistance; Genes, p53; Genome, Human; Germ-Line Mutation; Humans; Li-Fraumeni Syndrome; Neoplasms; Papillomaviridae; Phosphonoacetic Acid | 1994 |
[Chemotherapy in cancers of the colon].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Interferons; Interleukin-2; Leucovorin; Phosphonoacetic Acid | 1993 |
[Chemotherapy of metastasizing cancers of the colon and rectum].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Fluorouracil; Humans; Interferons; Leucovorin; Methotrexate; Neoplasm Metastasis; Phosphonoacetic Acid; Rectal Neoplasms | 1993 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phosphonoacetic Acid; Trimetrexate | 1994 |
Biochemical modulation of 5-fluorouracil by PALA: mechanism of action.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Fluorouracil; Humans; Immunologic Factors; Phosphonoacetic Acid | 1993 |
Recent advances in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Hydroxyurea; Infusions, Intra-Arterial; Leucovorin; Methotrexate; Neoplasm Staging; Phosphonoacetic Acid; Prospective Studies; Randomized Controlled Trials as Topic | 1993 |
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Interferons; Leucovorin; Liver Neoplasms; Methotrexate; Phosphonoacetic Acid | 1995 |
Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; DNA Damage; Drug Resistance; Fluorouracil; Humans; Methotrexate; Phosphonoacetic Acid; Purines; Pyrimidines; Tumor Suppressor Protein p53 | 1997 |
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; Dipyridamole; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Female; Fluorouracil; Humans; Immunologic Factors; Infusions, Intravenous; Injections, Intravenous; Interferons; Leucovorin; Liver Neoplasms; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Nucleotides; Palliative Care; Phosphonoacetic Acid; Randomized Controlled Trials as Topic; Thymidylate Synthase | 1996 |
Biomodulation of Fluorouracil in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Humans; Interferon-alpha; Leucovorin; Methotrexate; Phosphonoacetic Acid; Trimetrexate | 1998 |
Where do we stand with 5-fluorouracil?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chronotherapy; Colorectal Neoplasms; Dipyridamole; Drug Synergism; Fluorouracil; Humans; Interferons; Leucovorin; Levamisole; Methotrexate; Phosphonoacetic Acid; Radiation-Sensitizing Agents; Trimetrexate; Zidovudine | 1999 |
36 trial(s) available for phosphonoacetic acid and aspartic acid
| Article | Year |
|---|---|
A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Female; Fluorouracil; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasms, Unknown Primary; Phosphonoacetic Acid; Phosphoribosyl Pyrophosphate; Uridine Triphosphate | 1992 |
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Pancreatic Neoplasms; Phosphonoacetic Acid; Survival Analysis | 1992 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Drug Interactions; Female; Fluorouracil; Humans; Male; Methylthioinosine; Middle Aged; Neoplasms; Phosphonoacetic Acid; Phosphoribosyl Pyrophosphate | 1991 |
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Aspartic Acid; Colorectal Neoplasms; Drug Evaluation; Fluorouracil; Humans; Hyperbilirubinemia; Liver Neoplasms; Male; Phosphonoacetic Acid; Prothrombin Time; Retrospective Studies; Serum Albumin; Syndrome; Transaminases | 1991 |
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Breast Neoplasms; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Neoplasms; Phosphonoacetic Acid; Prognosis | 1991 |
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Administration Schedule; Drug Evaluation; Drug Synergism; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphonoacetic Acid; Survival Rate | 1991 |
A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Dipyridamole; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phosphonoacetic Acid; Sarcoma; Soft Tissue Neoplasms | 1991 |
A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer.
Topics: Adult; Aged; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug Evaluation; Drug Synergism; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Phosphonoacetic Acid; Stomach Neoplasms; Thymidine | 1990 |
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Levamisole; Male; Middle Aged; Neoplasm Metastasis; Phosphonoacetic Acid; Random Allocation; Rectal Neoplasms; Semustine; Streptozocin; Thymidine; Vincristine | 1985 |
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; Organophosphorus Compounds; Pancreatic Neoplasms; Phosphonoacetic Acid; Random Allocation; Rectal Neoplasms | 1988 |
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cimetidine; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Phosphonoacetic Acid; Pleural Neoplasms; Soft Tissue Neoplasms | 1987 |
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Topics: Animals; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid | 1985 |
A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Breast Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Organophosphorus Compounds; Phosphonoacetic Acid; Random Allocation | 1985 |
Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579).
Topics: Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Drug Evaluation; Humans; Lung Neoplasms; Phosphonoacetic Acid; Random Allocation; Teniposide; Zinostatin | 1984 |
Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.
Topics: Adult; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials as Topic; Colonic Neoplasms; Female; Humans; Male; Middle Aged; Nausea; Phosphonoacetic Acid; Rectal Neoplasms; Stomatitis | 1983 |
Phase II study of PALA and PCNU in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Phosphonoacetic Acid; Random Allocation | 1984 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phosphonoacetic Acid; Trimetrexate | 1994 |
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphonoacetic Acid; Survival Rate | 1995 |
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Aspartic Acid; Female; Fluorouracil; Humans; Male; Methylthioinosine; Middle Aged; Pancreatic Neoplasms; Phosphonoacetic Acid | 1994 |
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Digestive System; Drug Synergism; Female; Fluorouracil; Folic Acid; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Neutropenia; Phosphonoacetic Acid; Proportional Hazards Models; Pyrimidines; Remission Induction; Risk Factors; Thymidylate Synthase | 1995 |
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Phosphonoacetic Acid; Rectal Neoplasms | 1994 |
Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Combined Modality Therapy; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphonoacetic Acid; Radiotherapy Dosage | 1994 |
Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
Topics: Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Dose-Response Relationship, Drug; Humans; Leukocytes, Mononuclear; Phosphonoacetic Acid | 1993 |
A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Aspartic Acid; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Monocytes; Neoplasm Metastasis; Phosphonoacetic Acid | 1993 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Phosphonoacetic Acid; RNA, Neoplasm; Thioinosine; Thionucleotides | 1996 |
Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Fluorouracil; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Phosphonoacetic Acid; Recombinant Proteins; Stomach Neoplasms | 1996 |
Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Phosphonoacetic Acid; Stomach Neoplasms; Survival Rate | 1996 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Colorectal Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Leucovorin; Male; Methylthioinosine; Middle Aged; Phosphonoacetic Acid | 1997 |
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Phosphonoacetic Acid; Survival Analysis; Treatment Outcome | 1997 |
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; Genes, p53; Head and Neck Neoplasms; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Phosphonoacetic Acid; Survival Analysis; Treatment Failure | 1998 |
Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Aspartic Acid; Dipyridamole; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leukocytes; Male; Middle Aged; Neoplasms; Phosphonoacetic Acid; Uridine Triphosphate | 1996 |
Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Immunologic Factors; Infusions, Intravenous; Injections, Intravenous; Injections, Subcutaneous; Interferon-alpha; Leucovorin; Male; Middle Aged; Phosphonoacetic Acid; Survival Analysis; Treatment Outcome | 1999 |
Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cance
Topics: Administration, Oral; Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Leucovorin; Male; Middle Aged; Phosphonoacetic Acid; Prognosis; Recombinant Proteins | 2001 |
High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Phosphonoacetic Acid; Survival Analysis; Treatment Outcome | 2003 |
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Phosphonoacetic Acid; Pilot Projects; Prospective Studies; Survival Rate; Treatment Outcome | 2004 |
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Phosphonoacetic Acid; Pilot Projects; Survival Rate; Treatment Outcome | 2004 |
380 other study(ies) available for phosphonoacetic acid and aspartic acid
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Bohr effect in Escherichia coli aspartate transcarbamylase. Linkages between substrate binding, proton binding, and conformational transitions.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Calorimetry; Carbamyl Phosphate; Escherichia coli; Hydrogen-Ion Concentration; Oxyhemoglobins; Phosphonoacetic Acid; Potentiometry; Protein Conformation; Protons; Spectrophotometry; Succinates | 1979 |
Analogs of L-aspartic acid in chemotherapy for cancer.
Topics: Adenylosuccinate Synthase; Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartate-Ammonia Ligase; Aspartic Acid; Cells, Cultured; Mice; Neoplasms, Experimental; Phosphonoacetic Acid | 1979 |
Chemotherapy of human colon cancer xenografts in athymic nude mice.
Topics: Acridines; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcinoma; Cell Line; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Lomustine; Male; Maytansine; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Organophosphorus Compounds; Phosphonoacetic Acid; Streptozocin; Transplantation, Heterologous; Triazines | 1977 |
Phase I trial of N-(phosphonacetyl)-L-aspartate.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Colonic Neoplasms; Diarrhea; Drug Eruptions; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid; Remission, Spontaneous; Stomatitis | 1979 |
Functionally important arginine residues of aspartate transcarbamylase.
Topics: Aldehydes; Arginine; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Chemical Phenomena; Chemistry; Cytosine Nucleotides; Enzyme Activation; Escherichia coli; Glyoxal; Hydroxymercuribenzoates; Kinetics; Ligands; Macromolecular Substances; Organophosphorus Compounds; Phosphonoacetic Acid; Protein Binding; Protein Conformation | 1977 |
Calorimetric analysis of aspartate transcarbamylase from Escherichia coli. Binding of substrates and substrate analogues to the native enzyme and catalytic subunit.
Topics: Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Calorimetry; Carbamyl Phosphate; Escherichia coli; Macromolecular Substances; Phosphonoacetic Acid; Protein Conformation; Thermodynamics | 1978 |
An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Biological Assay; Escherichia coli; Methods; Mice; Organophosphorus Compounds; Phosphonoacetic Acid; Spleen | 1978 |
Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells.
Topics: Animals; Aspartic Acid; Cell Line; Cricetinae; DNA Nucleotidyltransferases; DNA, Recombinant; Drug Resistance; Escherichia coli; Mesocricetus; Multienzyme Complexes; Mutation; Nucleic Acid Hybridization; Organophosphorus Compounds; Phosphonoacetic Acid; Plasmids; Protein Biosynthesis; RNA, Messenger; Transcription, Genetic; Transformation, Genetic; Uracil Nucleotides; Uridine Monophosphate | 1979 |
Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Biological Assay; Humans; In Vitro Techniques; Methods; Organophosphorus Compounds; Phosphonoacetic Acid; Rats; Time Factors | 1979 |
Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Topics: Animals; Aspartic Acid; Cells, Cultured; Female; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Organophosphorus Compounds; Orotic Acid; Phosphonoacetic Acid; Pyrazoles; Pyrimidine Nucleotides; Pyrimidines; Ribonucleosides; Uridine | 1979 |
Determination of N-(Phosphonacetyl)-L-aspartic acid (PALA) in dog serum and urine by gas chromatography and selected lon monitoring.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Chromatography, Gas; Dogs; Female; Mass Spectrometry; Organophosphorus Compounds; Phosphonoacetic Acid | 1979 |
Hematologic and histopathologic evaluation of N-(phosphonacetyl)-L-aspartate (PALA) in mice.
Topics: Animals; Aspartic Acid; Blood Cell Count; Blood Cells; Body Weight; Digestive System; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Organophosphorus Compounds; Phosphonoacetic Acid; Time Factors | 1979 |
Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Biological Transport; Drug Resistance; Female; Kinetics; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Organophosphorus Compounds; Phosphonoacetic Acid; Transplantation, Homologous | 1979 |
Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Cells, Cultured; Cyclophosphamide; Drug Evaluation, Preclinical; Glioma; Graft Rejection; Leukemia, Experimental; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Organophosphorus Compounds; Phosphonoacetic Acid | 1978 |
Gas chromatography and mass spectrometry of N-(phosphonacetyl)-L-aspartic acid.
Topics: Aspartic Acid; Chromatography, Gas; Mass Spectrometry; Organophosphorus Compounds; Phosphonoacetic Acid | 1978 |
Antiproliferative agents and differential survival between normal and cancer cells.
Topics: Adenocarcinoma; Aspartic Acid; Cell Cycle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Neoplasms, Experimental; Organophosphorus Compounds; Phosphonoacetic Acid; Thymidine | 1978 |
N-(Phosphonacetyl)-L-aspartate-resistant hamster cells overaccumulate a single mRNA coding for the multifunctional protein that catalyzes the first steps of UMP synthesis.
Topics: Animals; Aspartic Acid; Cell Line; Cricetinae; Drug Resistance; Kinetics; Mesocricetus; Organophosphorus Compounds; Phosphonoacetic Acid; Proteins; RNA, Messenger; Transcription, Genetic; Uracil Nucleotides; Uridine Monophosphate | 1979 |
Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Body Weight; Carbamates; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Organophosphorus Compounds; Phosphonoacetic Acid; Uridine | 1977 |
Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells.
Topics: Animals; Aspartic Acid; Cell Division; Cells, Cultured; Colonic Neoplasms; DNA, Neoplasm; Humans; Kinetics; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Organophosphorus Compounds; Phosphonoacetic Acid; Pyrimidines; Transplantation, Isogeneic; Uridine | 1977 |
Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; Drug Administration Schedule; Female; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Male; Melanoma; Mice; Neoplasms, Experimental; Organophosphorus Compounds; Osteosarcoma; Phosphonoacetic Acid | 1976 |
Fusions near telomeres occur very early in the amplification of CAD genes in Syrian hamster cells.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Ammonia); Cell Line; Chromosome Banding; Chromosome Mapping; Cricetinae; Dihydroorotase; Gene Amplification; Membrane Fusion; Mesocricetus; Models, Genetic; Phosphonoacetic Acid; Telomere | 1992 |
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Base Sequence; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Cycle; Cells, Cultured; Chromosome Deletion; Cytogenetics; Dihydroorotase; Embryo, Mammalian; Fibroblasts; Gene Amplification; Genes, p53; Germ Cells; Heterozygote; Humans; Li-Fraumeni Syndrome; Mice; Mice, Transgenic; Molecular Sequence Data; Multienzyme Complexes; Mutation; Phosphonoacetic Acid; Tumor Cells, Cultured | 1992 |
Chromosome rearrangements associated with CAD gene amplification. Experiments with cell hybrids.
Topics: Animals; Aspartic Acid; Cell Line; Drug Resistance; Flow Cytometry; Gene Amplification; Hybrid Cells; Karyotyping; L Cells; Mice; Phosphonoacetic Acid; Recombination, Genetic | 1992 |
Induction of gene amplification by 5-aza-2'-deoxycytidine.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Azacitidine; Blotting, Southern; Cell Line; Cricetinae; Decitabine; DNA; Dose-Response Relationship, Drug; Drug Resistance; Gene Amplification; Mesocricetus; Methylation; Phosphonoacetic Acid | 1992 |
Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination.
Topics: 6-Aminonicotinamide; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Fluorouracil; Mammary Neoplasms, Experimental; Methylthioinosine; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Orotic Acid; Phosphonoacetic Acid; Phosphoribosyl Pyrophosphate | 1992 |
Effects of replacement of active site residue glutamine 231 on activity and allosteric properties of aspartate transcarbamoylase.
Topics: Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Enzyme Activation; Escherichia coli; Glutamine; Kinetics; Ligands; Mutagenesis, Site-Directed; Phosphonoacetic Acid; Structure-Activity Relationship; Substrate Specificity | 1992 |
Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma.
Topics: Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Phosphonoacetic Acid; Retrospective Studies; Time Factors | 1992 |
The tryptophan residues of aspartate transcarbamylase: site-directed mutagenesis and time-resolved fluorescence spectroscopy.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Catalysis; Kinetics; Models, Chemical; Models, Molecular; Mutagenesis, Site-Directed; Phosphonoacetic Acid; Protein Conformation; Spectrometry, Fluorescence; Substrate Specificity; Tryptophan | 1992 |
Mechanism-based model for tumor drug resistance.
Topics: Animals; Aspartic Acid; Cell Cycle; Cell Survival; Dipyridamole; Dose-Response Relationship, Drug; Drug Resistance; Models, Biological; Models, Statistical; Phosphonoacetic Acid; Pyrimidines; Tumor Cells, Cultured; Uridine | 1992 |
Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.
Topics: Aspartic Acid; Base Sequence; Cell Cycle; Chromosome Deletion; Fibroblasts; G1 Phase; Gene Amplification; Genes, p53; Humans; Li-Fraumeni Syndrome; Molecular Sequence Data; Mutation; Phosphonoacetic Acid; S Phase; Suppression, Genetic; Tumor Cells, Cultured | 1992 |
Hepatotoxicity of fluorouracil with N-phosphonacetyl-L-aspartate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chemical and Drug Induced Liver Injury; Fluorouracil; Humans; Phosphonoacetic Acid | 1992 |
Suppression of gene amplification in human cell hybrids.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Cell Line; Cell Transformation, Neoplastic; Drug Resistance; Gene Amplification; Gene Expression Regulation, Enzymologic; Genes, Dominant; Genes, Recessive; Humans; Hybrid Cells; Mutation; Phenotype; Phosphonoacetic Acid; Suppression, Genetic; Tumor Cells, Cultured | 1992 |
Importance of a conserved residue, aspartate-162, for the function of Escherichia coli aspartate transcarbamoylase.
Topics: Adenosine Triphosphate; Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Computer Simulation; Cytidine Triphosphate; Escherichia coli; Kinetics; Models, Molecular; Molecular Structure; Mutagenesis, Site-Directed; Phosphonoacetic Acid; Structure-Activity Relationship | 1992 |
The emerging role for biomodulation of antineoplastic agents.
Topics: Antineoplastic Agents; Aspartic Acid; Dipyridamole; Fluorouracil; Humans; Immunologic Factors; Interferon-alpha; Phosphonoacetic Acid | 1992 |
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Leukocyte Count; Male; Middle Aged; Phosphonoacetic Acid | 1992 |
[Mechanism of the effect of serine and threonine on ammoniagenesis and biosynthesis of orotate in the mouse].
Topics: Adenine; Ammonia; Animals; Aspartic Acid; Cycloheximide; Male; Mice; Mice, Inbred ICR; Orotic Acid; Phosphonoacetic Acid; Serine; Threonine | 1992 |
Ionization of amino acid residues involved in the catalytic mechanism of aspartate transcarbamoylase.
Topics: Amino Acids; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Carbon Radioisotopes; Catalysis; Escherichia coli; Hydrogen-Ion Concentration; Ions; Kinetics; Phosphonoacetic Acid; Recombinant Proteins | 1992 |
Steady-state kinetics and isotope effects on the mutant catalytic trimer of aspartate transcarbamoylase containing the replacement of histidine 134 by alanine.
Topics: Alanine; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbon Isotopes; Catalysis; Histidine; Hydrogen-Ion Concentration; In Vitro Techniques; Kinetics; Macromolecular Substances; Models, Molecular; Mutation; Phosphonoacetic Acid; Recombinant Proteins; Structure-Activity Relationship; Succinates | 1992 |
The contribution of threonine 55 to catalysis in aspartate transcarbamoylase.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Base Sequence; Carbamyl Phosphate; Carbon Isotopes; Catalysis; Deuterium; Hydrogen-Ion Concentration; Molecular Sequence Data; Mutagenesis, Site-Directed; Nitrogen Isotopes; Oligonucleotides; Phosphonoacetic Acid; Structure-Activity Relationship; Succinates; Threonine | 1992 |
13C isotope effect studies of Escherichia coli aspartate transcarbamylase in the presence of the bisubstrate analog N-(phosphonoacetyl)-L-aspartate.
Topics: Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Carbon Isotopes; Escherichia coli; Hydrogen-Ion Concentration; Kinetics; Phosphonoacetic Acid | 1992 |
5-Iododeoxyuridine increases the efficacy of the radioimmunotherapy of human tumors growing in nude mice.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Deoxycytidine; Drug Therapy, Combination; Humans; Idoxuridine; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphonoacetic Acid; Radiation-Sensitizing Agents; Radioimmunotherapy; Tetrahydrouridine; Transplantation, Heterologous | 1992 |
Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Carcinoma, Squamous Cell; Cell Division; Chromosome Deletion; Dihydroorotase; DNA Replication; Drug Resistance; Gene Amplification; Humans; Hydroxyurea; Methotrexate; Multienzyme Complexes; Phosphonoacetic Acid; Plasmids; Tumor Cells, Cultured; Vinblastine | 1991 |
Long range effects of amino acid substitutions in the catalytic chain of aspartate transcarbamoylase. Localized replacements in the carboxyl-terminal alpha-helix cause marked alterations in allosteric properties and intersubunit interactions.
Topics: Allosteric Regulation; Amino Acids; Aspartate Carbamoyltransferase; Aspartic Acid; Catalysis; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Kinetics; Mutation; Phosphonoacetic Acid; Protein Conformation; Spectrophotometry, Ultraviolet | 1992 |
Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasms; Phosphonoacetic Acid | 1992 |
Clinical trials referral resource. Treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Phosphonoacetic Acid | 1991 |
[Segments of Djungarian hamster chromosomes, specific for translocation of integration of amplified mdr1 genes, do not possess increased instability].
Topics: Animals; Antineoplastic Agents; Aphidicolin; Aspartic Acid; Chromosome Fragile Sites; Chromosome Fragility; Chromosomes; Cricetinae; Floxuridine; Gene Amplification; Nucleic Acid Hybridization; Phosphonoacetic Acid; Translocation, Genetic | 1991 |
Biochemical modulation: a modality that has come of therapeutic age.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Breast Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Mitoxantrone; Phosphonoacetic Acid | 1991 |
Different amino acid substitutions at the same position in the nucleotide-binding site of aspartate transcarbamoylase have diverse effects on the allosteric properties of the enzyme.
Topics: Adenosine Triphosphate; Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Cytidine Triphosphate; DNA Mutational Analysis; Histidine; Lysine; Phosphonoacetic Acid; Structure-Activity Relationship | 1991 |
Structural consequences of the replacement of Glu239 by Gln in the catalytic chain of Escherichia coli aspartate transcarbamylase.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; Cytidine Triphosphate; Escherichia coli; Glutamates; Glutamic Acid; Glutamine; Phosphonoacetic Acid; Protein Engineering; Structure-Activity Relationship; X-Ray Diffraction | 1990 |
Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts.
Topics: Aspartic Acid; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplastic; Drug Resistance; Fibroblasts; Gene Amplification; Humans; Methotrexate; Phenotype; Phosphonoacetic Acid | 1991 |
Function of serine-171 in domain closure, cooperativity, and catalysis in Escherichia coli aspartate transcarbamoylase.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Catalysis; Escherichia coli; Kinetics; Mutation; Phosphonoacetic Acid; Protein Conformation; Serine; Structure-Activity Relationship; Substrate Specificity | 1990 |
High frequency of double drug resistance in the B16 melanoma cell line.
Topics: Amides; Animals; Antineoplastic Agents; Aspartic Acid; Cell Line; Colony-Forming Units Assay; Drug Resistance; Drug Synergism; Gene Amplification; Melanoma; Methotrexate; Mice; Ouabain; Phosphonoacetic Acid; Pyrazoles; Ribonucleosides; Ribose | 1990 |
Phosphorus-containing inhibitors of aspartate transcarbamoylase from Escherichia coli.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Diphosphates; Escherichia coli; Magnetic Resonance Spectroscopy; Molecular Structure; Phosphonoacetic Acid; Structure-Activity Relationship; Sulfhydryl Compounds | 1990 |
Importance of domain closure for homotropic cooperativity in Escherichia coli aspartate transcarbamylase.
Topics: Adenosine Triphosphate; Alanine; Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Cytidine Triphosphate; Enzyme Activation; Escherichia coli; Kinetics; Mutation; Phosphonoacetic Acid; Succinates | 1990 |
Heterotropic effectors promote a global conformational change in aspartate transcarbamoylase.
Topics: Adenosine Triphosphate; Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Cytidine Triphosphate; Escherichia coli; Kinetics; Mutation; Phosphonoacetic Acid; Protein Conformation | 1990 |
Importance of residues Arg-167 and Gln-231 in both the allosteric and catalytic mechanisms of Escherichia coli aspartate transcarbamoylase.
Topics: Adenosine Triphosphate; Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Catalysis; Cytidine Triphosphate; Escherichia coli; Glutamine; Kinetics; Mutation; Phosphonoacetic Acid; Protein Conformation | 1990 |
The catalytic site of Escherichia coli aspartate transcarbamylase: interaction between histidine 134 and the carbonyl group of the substrate carbamyl phosphate.
Topics: Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Bacterial Proteins; Binding Sites; Carbamyl Phosphate; Catalysis; Escherichia coli; Histidine; Hydrogen-Ion Concentration; Kinetics; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Phosphonoacetic Acid; Protein Binding; Substrate Specificity; Succinates; Succinic Acid | 1990 |
Co-operative interactions between the catalytic sites in Escherichia coli aspartate transcarbamylase. Role of the C-terminal region of the regulatory chains.
Topics: Allosteric Site; Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Escherichia coli; Hydrogen-Ion Concentration; Kinetics; Macromolecular Substances; Models, Molecular; Models, Structural; Molecular Sequence Data; Mutagenesis, Insertional; Phosphonoacetic Acid; Plasmids; Protein Binding; Protein Conformation; Restriction Mapping | 1990 |
Normal diploid human and rodent cells lack a detectable frequency of gene amplification.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Cell Division; Cells, Cultured; Diploidy; Drug Resistance; Fibroblasts; Gene Amplification; Humans; Methotrexate; Phenotype; Phosphonoacetic Acid; Rats; Reference Values; Species Specificity; Tumor Cells, Cultured | 1990 |
Synthesis and biological activity of a series of aspartate transcarbamoylase inhibitors: N-substituted diethyl aspartates and N-substituted-3-oxo-1,4-piperazine-2-acetic acid esters.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Chemical Phenomena; Chemistry, Physical; Drug Screening Assays, Antitumor; Microbial Sensitivity Tests; Phosphonoacetic Acid | 1990 |
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; Phosphonoacetic Acid; Survival Analysis | 1990 |
Radiation, pool size and incorporation studies in mice with 5-chloro-2'-deoxycytidine.
Topics: Animals; Aspartic Acid; Combined Modality Therapy; Cytidine Deaminase; Deoxycytidine; DNA, Neoplasm; Drug Therapy, Combination; Mice; Mice, Inbred C3H; Phosphonoacetic Acid; Radiation-Sensitizing Agents; Sarcoma, Experimental; Tetrahydrouridine; Uracil; Uridine Phosphorylase | 1990 |
Introduction to 5-fluorouracil modulation.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Phosphonoacetic Acid; Uridine | 1990 |
Biochemical modulation of 5-fluorouracil by PALA.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Drug Evaluation; Drug Synergism; Fluorouracil; Humans; Phosphonoacetic Acid | 1990 |
Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Female; Fluorouracil; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasms; Phosphonoacetic Acid; Uridine | 1990 |
New RNA species is produced by alternate polyadenylation following rearrangement associated with CAD gene amplification.
Topics: Animals; Aspartic Acid; Base Sequence; Cell Line; Chromosome Mapping; Cricetinae; DNA; DNA Restriction Enzymes; Drug Resistance; Gene Amplification; Phosphonoacetic Acid; Poly A; RNA; Transfection | 1986 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bone Marrow; Carcinoma, Squamous Cell; Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Methotrexate; Pentosephosphates; Phosphonoacetic Acid; Phosphoribosyl Pyrophosphate | 1989 |
Structural organization and expression of amplified chromosomal sequences, which include the rudimentary gene, in cultured Drosophila cells resistant to N-(phosphonacetyl)-L-aspartate.
Topics: Animals; Aspartic Acid; Base Sequence; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Chromosome Mapping; DNA; Drosophila; Drug Resistance; Gene Amplification; Gene Expression; Genes; Molecular Sequence Data; Phosphonoacetic Acid; RNA | 1989 |
Function of threonine-55 in the carbamoyl phosphate binding site of Escherichia coli aspartate transcarbamoylase.
Topics: Alanine; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Escherichia coli; Kinetics; Molecular Structure; Mutation; Phosphonoacetic Acid; Protein Conformation; Threonine | 1989 |
The presence of amplified regions affects the stability of chromosomes in drug-resistant Chinese hamster cells.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Cycle; Cell Line; Chromosomes; Cricetinae; Cricetulus; Dihydroorotase; Drug Resistance; Gene Amplification; Methotrexate; Multienzyme Complexes; Neoplasm Proteins; Phosphonoacetic Acid; Tetrahydrofolate Dehydrogenase | 1989 |
Evolution and stability of chromosomal DNA coamplified with the CAD gene.
Topics: Amidohydrolases; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Biological Evolution; Blotting, Southern; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Chromosomes; Cricetinae; Dihydroorotase; DNA; Gene Amplification; Models, Genetic; Multienzyme Complexes; Mutation; Phosphonoacetic Acid | 1989 |
Structure of four amplified DNA novel joints.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Base Composition; Base Sequence; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Cloning, Molecular; Crossing Over, Genetic; Dihydroorotase; DNA; Drug Resistance; Gene Amplification; Models, Genetic; Molecular Sequence Data; Multienzyme Complexes; Mutation; Phosphonoacetic Acid; Recombination, Genetic; Restriction Mapping | 1989 |
1-beta-D-arabinofuranosylcytosine enhancement of resistance to several antineoplastic drugs in mammalian tissue culture cells.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Cricetinae; Cytarabine; Dihydroorotase; Dose-Response Relationship, Drug; Drug Resistance; Floxuridine; Gene Amplification; Methotrexate; Multienzyme Complexes; Phosphonoacetic Acid; Time Factors; Vincristine | 1989 |
The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites.
Topics: Animals; Aspartic Acid; Cell Line; Cells, Cultured; Fluorouracil; Humans; Methotrexate; Neoplasms; Ornithine Decarboxylase; Orotate Phosphoribosyltransferase; Pentosephosphates; Phosphonoacetic Acid; Phosphoribosyl Pyrophosphate | 1985 |
Cooperative binding of the bisubstrate analog N-(phosphonacetyl)-L-aspartate to aspartate transcarbamoylase and the heterotropic effects of ATP and CTP.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Cytidine Triphosphate; Cytosine Nucleotides; Escherichia coli; Kinetics; Macromolecular Substances; Organophosphorus Compounds; Phosphonoacetic Acid; Protein Binding; Radioisotope Dilution Technique; Tritium | 1989 |
Analysis of the ligand-promoted global conformational change in aspartate transcarbamoylase. Evidence for a two-state transition from boundary spreading in sedimentation velocity experiments.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Escherichia coli; Ligands; Molecular Conformation; Phosphonoacetic Acid; Ultracentrifugation | 1989 |
Boundary spreading in sedimentation velocity experiments on partially liganded aspartate transcarbamoylase. A ligand-mediated isomerization.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Biological Transport; Escherichia coli; Isomerism; Ligands; Phosphonoacetic Acid; Ultracentrifugation | 1989 |
Discrimination between nucleotide effector responses of aspartate transcarbamoylase due to a single site substitution in the allosteric binding site.
Topics: Adenosine Triphosphate; Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Cytidine Triphosphate; DNA Mutational Analysis; Enzyme Activation; Escherichia coli; Hydrogen-Ion Concentration; Kinetics; Models, Molecular; Phosphonoacetic Acid; Structure-Activity Relationship; Uridine Triphosphate | 1989 |
Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Cell Line; Clone Cells; Drug Resistance; Gene Amplification; Genetic Techniques; Liver; Mutation; Phosphonoacetic Acid; Rats; Tumor Cells, Cultured | 1989 |
Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cytidine; Deoxyribonucleotides; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Phosphonoacetic Acid; Ribonucleotides; Tumor Cells, Cultured | 1989 |
Pyrimidine pathways enzymes in human tumors of brain and associated tissues: potentialities for the therapeutic use of N-(phosphonacetyl-L-aspartate and 1-beta-D-arabinofuranosylcytosine.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Brain; Brain Neoplasms; Cytarabine; Cytidine Deaminase; Humans; Meningeal Neoplasms; Nucleoside Deaminases; Nucleoside-Phosphate Kinase; Phosphonoacetic Acid; Phosphotransferases; Pyrimidines | 1987 |
Overproduction of the first three enzymes of pyrimidine nucleotide biosynthesis in Drosophila cells resistant to N-phosphonacetyl-L-aspartate.
Topics: Amidohydrolases; Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Ammonia); Cells, Cultured; Clone Cells; Dihydroorotase; Drosophila melanogaster; Drug Resistance; Karyotyping; Ligases; Organophosphorus Compounds; Phosphonoacetic Acid; Pyrimidine Nucleotides | 1986 |
Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
Topics: Amides; Aspartate Carbamoyltransferase; Aspartic Acid; Breast Neoplasms; Carbamoyl-Phosphate Synthase (Ammonia); Cell Line; Dihydroorotase; Drug Resistance; Female; Humans; Orotate Phosphoribosyltransferase; Orotidine-5'-Phosphate Decarboxylase; Phosphonoacetic Acid; Pyrazoles; Pyrimidines; Ribonucleosides; Ribose; Uracil Nucleotides; Uridine | 1986 |
Aspartate transcarbamylase from Leishmania donovani. A discrete, nonregulatory enzyme as a potential chemotherapeutic site.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Ammonia); Chromatography, Gel; Cricetinae; Dihydroorotase; Leishmania donovani; Leishmaniasis; Organophosphorus Compounds; Pentamidine; Phosphonoacetic Acid | 1988 |
Chromosome aberrations associated with CAD gene amplification in Chinese hamster cultured cells.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Chromosome Aberrations; Chromosome Banding; Cricetinae; Cricetulus; Dihydroorotase; Drug Resistance; Gene Amplification; Genes; Multienzyme Complexes; Neoplasm Proteins; Phosphonoacetic Acid | 1988 |
Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Cell Line; Drug Resistance; Fibrosarcoma; Gene Amplification; Methotrexate; Mice; Neoplasm Metastasis; Organophosphorus Compounds; Phosphonoacetic Acid | 1989 |
Increased incidence of CAD gene amplification in tumorigenic rat lines as an indicator of genomic instability of neoplastic cells.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Drug Resistance; Epithelium; Gene Amplification; Liver Neoplasms, Experimental; Neoplasm Transplantation; Phosphonoacetic Acid; Rats; Rats, Inbred F344; Tumor Cells, Cultured | 1989 |
Structure of DNA formed in the first step of CAD gene amplification.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Cloning, Molecular; Cosmids; Dihydroorotase; DNA; DNA Restriction Enzymes; Gene Amplification; Genes; Multienzyme Complexes; Mutation; Phosphonoacetic Acid; Proteins; Repetitive Sequences, Nucleic Acid | 1986 |
The role of an active site histidine in the catalytic mechanism of aspartate transcarbamoylase.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Escherichia coli; Histidine; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Phosphonoacetic Acid; Succinates; Succinic Acid | 1988 |
Complex of N-phosphonacetyl-L-aspartate with aspartate carbamoyltransferase. X-ray refinement, analysis of conformational changes and catalytic and allosteric mechanisms.
Topics: Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Escherichia coli; Ligands; Macromolecular Substances; Models, Molecular; Molecular Conformation; Molecular Sequence Data; Organophosphorus Compounds; Phosphonoacetic Acid; X-Ray Diffraction; Zinc | 1988 |
Carrot cells detoxify N-phosphonoacetyl-L-aspartate by esterification.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Chromatography, Gas; Chromatography, Ion Exchange; Esterification; Inactivation, Metabolic; Organophosphorus Compounds; Phosphonoacetic Acid; Plants | 1988 |
Effectors of Escherichia coli aspartate transcarbamoylase differentially perturb aspartate binding rather than the T-R transition.
Topics: Adenosine Triphosphate; Algorithms; Aspartate Carbamoyltransferase; Aspartic Acid; Cytidine Triphosphate; Escherichia coli; Hydrogen-Ion Concentration; Kinetics; Phosphonoacetic Acid | 1988 |
Site-specific substitutions of the Tyr-165 residue in the catalytic chain of aspartate transcarbamoylase promotes a T-state preference in the holoenzyme.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Escherichia coli; Hydroxymercuribenzoates; Kinetics; Mutation; Phosphonoacetic Acid; Structure-Activity Relationship; Tyrosine; X-Ray Diffraction | 1988 |
Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Cell Division; Cytidine; Liver Neoplasms, Experimental; Organophosphorus Compounds; Orotic Acid; Phosphonoacetic Acid; Pyrimidine Nucleosides; Pyrimidines; Rats; Tumor Cells, Cultured; Uridine | 1988 |
TPA enhancement of the recovery of methotrexate and N-phosphonacetyl L-aspartate resistant mouse 3T6 cell clones is associated with transient alterations of cell cycle progression.
Topics: Animals; Aspartic Acid; Cell Cycle; Cell Line; Cell Survival; Cricetinae; Drug Interactions; Drug Resistance; Interphase; Methotrexate; Mice; Organophosphorus Compounds; Phosphonoacetic Acid; Tetradecanoylphorbol Acetate | 1988 |
Phenotypic resistance to methotrexate and N-phosphonacetyl L-aspartate is induced by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA).
Topics: Animals; Aspartic Acid; Cell Line; Drug Interactions; Drug Resistance; Gene Amplification; Methotrexate; Organophosphorus Compounds; Phenotype; Phosphonoacetic Acid; Tetradecanoylphorbol Acetate; Tetrahydrofolate Dehydrogenase | 1988 |
Communication between polypeptide chains in aspartate transcarbamoylase. Conformational changes at the active sites of unliganded chains resulting from ligand binding to other chains.
Topics: Adenosine Triphosphate; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Cytidine Triphosphate; Escherichia coli; Kinetics; Macromolecular Substances; Phosphonoacetic Acid; Protein Conformation; Spectrophotometry | 1986 |
The binding of N-(phosphonacetyl)-L-aspartate to aspartate carbamoyltransferase of Escherichia coli.
Topics: Amino Acids; Aspartate Carbamoyltransferase; Aspartic Acid; Escherichia coli; Hydrogen Bonding; Organophosphorus Compounds; Phosphonoacetic Acid; Protein Binding; Substrate Specificity | 1986 |
Effect of amino acid substitutions on the catalytic and regulatory properties of aspartate transcarbamoylase.
Topics: Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Base Sequence; Escherichia coli; Genes; Genes, Bacterial; Genes, Regulator; Kinetics; Mutagens; Phosphonoacetic Acid; Templates, Genetic | 1986 |
The catalytic mechanism of Escherichia coli aspartate carbamoyltransferase: a molecular modelling study.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Chemical Phenomena; Chemistry; Escherichia coli; Hydrogen Bonding; Models, Chemical; Molecular Conformation; Phosphonoacetic Acid | 1987 |
In situ behavior of the pyrimidine pathway enzymes in Saccharomyces cerevisiae. 2. Reaction mechanism of aspartate transcarbamylase dissociated from carbamylphosphate synthetase by genetic alteration.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding, Competitive; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Electrophoresis, Polyacrylamide Gel; Hydrogen-Ion Concentration; Ligases; Molecular Weight; Mutation; Phosphonoacetic Acid; Saccharomyces cerevisiae | 1987 |
Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines.
Topics: Animals; Aspartic Acid; Cell Line; Drug Resistance; Gene Amplification; Mathematics; Melanoma; Methotrexate; Mice; Neoplasm Metastasis; Organophosphorus Compounds; Phenotype; Phosphonoacetic Acid | 1987 |
Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis.
Topics: 3-Deazauridine; Amides; Aspartic Acid; Cell Division; Cell Line; Deoxycytidine; Deoxycytidine Kinase; Drug Interactions; Humans; Leukemia, Experimental; Phosphonoacetic Acid; Pyrazoles; Pyrimidines; Ribonucleosides; Ribose; Thymidine | 1987 |
2.5 A structure of aspartate carbamoyltransferase complexed with the bisubstrate analog N-(phosphonacetyl)-L-aspartate.
Topics: Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Macromolecular Substances; Molecular Conformation; Organophosphorus Compounds; Phosphonoacetic Acid; X-Ray Diffraction | 1987 |
Unstable and stable CAD gene amplification: importance of flanking sequences and nuclear environment in gene amplification.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Base Sequence; Cell Line; Cell Nucleus; Drug Resistance; Gene Amplification; Genes; Hybrid Cells; Karyotyping; Mice; Nucleic Acid Hybridization; Phosphonoacetic Acid; Sarcoma 180 | 1987 |
Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dipyridamole; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid; Uridine | 1986 |
Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Leukemia P388; Leukemia, Experimental; Mice; Phosphonoacetic Acid; Ribavirin; Ribonucleosides; Thioguanine | 1986 |
Failure of L-histidinol to improve the therapeutic efficiency of 5-fluorouracil against murine breast tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cell Cycle; Female; Fluorouracil; Histidinol; Imidazoles; Lethal Dose 50; Leukemia L1210; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Phosphonoacetic Acid | 1987 |
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Central Nervous System Diseases; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Metastasis; Phosphonoacetic Acid; Pilot Projects; Rectal Neoplasms | 1987 |
Hamster cells with increased rates of DNA amplification, a new phenotype.
Topics: Amides; Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Cell Line; Coformycin; Cricetinae; DNA; Drug Resistance; Gene Amplification; Genes; Kidney; Methotrexate; Mutation; Ouabain; Phenotype; Phosphonoacetic Acid; Pyrazoles; Ribonucleosides; Ribose; Tetrahydrofolate Dehydrogenase | 1987 |
Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dipyridamole; Drug Evaluation; Drug Synergism; Female; Gastrointestinal Diseases; Headache; Humans; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid; Uridine | 1987 |
Structure at 2.9-A resolution of aspartate carbamoyltransferase complexed with the bisubstrate analogue N-(phosphonacetyl)-L-aspartate.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Phosphonoacetic Acid; Protein Conformation; X-Ray Diffraction | 1985 |
Modulation of the activity of PALA by dipyridamole.
Topics: Animals; Aspartic Acid; Biological Transport; Cell Line; Colonic Neoplasms; Dipyridamole; Drug Interactions; Humans; In Vitro Techniques; Lethal Dose 50; Leukemia, Myeloid; Melanoma; Mice; Mice, Nude; Organophosphorus Compounds; Phosphonoacetic Acid; Pyrimidine Nucleosides; Tritium; Uridine | 1985 |
Cancer chemotherapy: past is prologue.
Topics: 6-Aminonicotinamide; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Fluorouracil; Humans; Male; Mammary Neoplasms, Experimental; Methotrexate; Methylthioinosine; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Phosphonoacetic Acid | 1985 |
Quaternary structure changes in aspartate transcarbamylase studied by X-ray solution scattering. Signal transmission following effector binding.
Topics: Adenosine Triphosphate; Allosteric Site; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Cytidine Triphosphate; Escherichia coli; Macromolecular Substances; Phosphonoacetic Acid; X-Rays | 1985 |
On conformational changes in the regulatory enzyme aspartate transcarbamoylase.
Topics: Allosteric Regulation; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Enzyme Activation; Escherichia coli; Kinetics; Macromolecular Substances; Magnetic Resonance Spectroscopy; Phosphonoacetic Acid; Protein Conformation | 1985 |
Homotropic effects in aspartate transcarbamoylase. What happens when the enzyme binds a single molecule of the bisubstrate analog N-phosphonacetyl-L-aspartate?
Topics: Adenosine Triphosphate; Allosteric Site; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Cytidine Triphosphate; Escherichia coli; Kinetics; Nucleotides; Organophosphorus Compounds; Phosphonoacetic Acid; Thermodynamics | 1985 |
Kinetics of the interaction of N-(phosphonacetyl)-L-aspartate with the catalytic subunit of aspartate transcarbamoylase. A slow conformational change subsequent to binding.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Kinetics; Macromolecular Substances; Magnetic Resonance Spectroscopy; Mathematics; Organophosphorus Compounds; Phosphonoacetic Acid; Protein Conformation | 1986 |
[Biochemical modulation of 5-FU by thymidine and N-phosphoacetyl-L-aspartate: the relation between 5-FU incorporation into RNA and its cytocidal effect].
Topics: Animals; Aspartic Acid; Cell Division; Cell Survival; Cells, Cultured; DNA, Neoplasm; Drug Synergism; Female; Fluorouracil; Mammary Neoplasms, Experimental; Mice; Organophosphorus Compounds; Phosphonoacetic Acid; RNA, Neoplasm; Thymidine; Tumor Stem Cell Assay | 1986 |
Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cell Line; Dipyridamole; Drug Synergism; Female; Humans; Nucleotides; Organophosphorus Compounds; Ovarian Neoplasms; Phosphonoacetic Acid; Uridine | 1985 |
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Drug Evaluation; Fluorouracil; Humans; Middle Aged; Phosphonoacetic Acid; Rectal Neoplasms; Thymidine | 1985 |
19F nuclear magnetic resonance studies of fluorotyrosine-labeled aspartate transcarbamoylase. Properties of the enzyme and its catalytic and regulatory subunits.
Topics: Adenosine Triphosphate; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Cytidine Triphosphate; Magnetic Resonance Spectroscopy; Phosphonoacetic Acid; Tyrosine | 1985 |
19F nuclear magnetic resonance studies of communication between catalytic and regulatory subunits in aspartate transcarbamoylase.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Kinetics; Magnetic Resonance Spectroscopy; Phosphonoacetic Acid; Protein Conformation; Tyrosine | 1985 |
N-(Phosphonoacetyl)amino phosphonates. Phosphonate analogues of N-(phosphonoacetyl)-L-aspartic acid (PALA).
Topics: Aspartic Acid; Cell Line; Chemical Phenomena; Chemistry; Humans; Mouth Neoplasms; Organophosphonates; Organophosphorus Compounds; Phosphonoacetic Acid; Structure-Activity Relationship | 1985 |
Design and synthesis of new transition-state analogue inhibitors of aspartate transcarbamylase.
Topics: Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Binding, Competitive; Carbamyl Phosphate; Chemical Phenomena; Chemistry; Kinetics; Organophosphorus Compounds; Organothiophosphorus Compounds; Phosphonoacetic Acid; Structure-Activity Relationship | 1985 |
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinoma, Bronchogenic; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Fluorouracil; Half-Life; Humans; Infusions, Parenteral; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Stomach Neoplasms; Thymidine | 1985 |
Chemotherapy and hormonal therapy of mouse mammary tumors.
Topics: Animals; Aspartic Acid; Body Weight; Cholesterol; Cisplatin; Delayed-Action Preparations; Doxorubicin; Female; Injections, Intraperitoneal; Mammary Neoplasms, Experimental; Mice; Organophosphorus Compounds; Ovariectomy; Phosphonoacetic Acid; Receptors, Estrogen; Receptors, Progesterone | 1985 |
N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Bicarbonates; Carbamates; Carbon Radioisotopes; Cell Division; Cell Line; Cell Transformation, Neoplastic; Cells, Cultured; Chromatography, Ion Exchange; Fibroblasts; Haplorhini; Kidney; Kinetics; Mice; Mice, Inbred Strains; Organophosphonates; Organophosphorus Compounds; Phosphonoacetic Acid; Simian virus 40; Species Specificity; Time Factors; Tritium; Uridine | 1974 |
Inhibition by N-(phosphonacetyl)-L-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice.
Topics: Administration, Oral; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbon Radioisotopes; Cell Division; DNA; Female; Injections, Subcutaneous; Isoproterenol; Jejunum; Mice; Organophosphonates; Phosphonoacetic Acid; Spleen; Submandibular Gland; Thymidine; Time Factors; Tritium | 1974 |
Aspartate transcarbamylase. Interaction with the transition state analogue N-(phosphonacetyl)-L-aspartate.
Topics: Acetates; Aspartic Acid; Binding Sites; Carbamates; Catalysis; Chemical Phenomena; Chemistry; Drug Stability; Escherichia coli; Hydrazines; Lithium; Maleates; Mathematics; Organophosphonates; Phosphonoacetic Acid; Phosphoric Acids; Protein Binding; Protein Conformation; Spectrophotometry; Succinates; Transferases; Ultraviolet Rays | 1971 |
Response of psoriasis to N-phosphonacetyl-L-aspartate.
Topics: Adult; Aspartic Acid; Humans; Male; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Psoriasis | 1981 |
Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Azacitidine; Cell Division; Cytidine; DNA, Neoplasm; Leukemia L1210; Leukemia, Experimental; Mice; Neoplasm Proteins; Organophosphorus Compounds; Phosphonoacetic Acid; RNA, Neoplasm; Uridine | 1981 |
Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonacetyl)-L-aspartate.
Topics: Animals; Aspartic Acid; Azauridine; DNA, Neoplasm; Drug Therapy, Combination; Female; Galactosamine; Liver; Liver Neoplasms, Experimental; Organophosphorus Compounds; Phosphonoacetic Acid; Rats; RNA, Neoplasm; Stimulation, Chemical; Uracil Nucleotides; Uridine | 1980 |
Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
Topics: Amides; Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Azauridine; Galactosamine; Liver; Male; Mice; Organophosphorus Compounds; Phosphonoacetic Acid; Pyrazoles; Pyrimidines; Ribonucleosides; Ribose; Uridine | 1981 |
Single-copy and amplified CAD genes in Syrian hamster chromosomes localized by a highly sensitive method for in situ hybridization.
Topics: Animals; Aspartic Acid; Cells, Cultured; Chromosome Aberrations; Chromosome Mapping; Cricetinae; Dextran Sulfate; Dextrans; DNA; DNA, Recombinant; Drug Resistance; Gene Amplification; Karyotyping; Kidney; Mesocricetus; Multienzyme Complexes; Nucleic Acid Hybridization; Phosphonoacetic Acid | 1982 |
Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
Topics: Animals; Aspartic Acid; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Organophosphorus Compounds; Phosphonoacetic Acid; RNA | 1983 |
Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
Topics: Animals; Aspartic Acid; Blood Proteins; Dogs; Drug Interactions; Fluorouracil; Kinetics; Organophosphorus Compounds; Phosphonoacetic Acid; Pyrimidines; RNA; Tissue Distribution | 1983 |
Fluctuations in phosphoribosyl pyrophosphate levels in monolayer tumor cell lines. Effects of drugs.
Topics: Animals; Aspartic Acid; Buffers; Cell Line; Cytological Techniques; Fibroblasts; Humans; Melanoma; Methotrexate; Mice; Pentosephosphates; Phosphonoacetic Acid; Phosphoribosyl Pyrophosphate; Purine Nucleosides; Trypsin | 1984 |
Peritoneo-cystic shunt for malignant ascites.
Topics: Ascites; Aspartic Acid; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Palliative Care; Peritoneum; Phosphonoacetic Acid; Suction; Tamoxifen; Urinary Bladder | 1984 |
N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Breast Neoplasms; Digestive System; Drug Eruptions; Drug Evaluation; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Metastasis; Organophosphorus Compounds; Phosphonoacetic Acid | 1982 |
N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Digestive System; Drug Eruptions; Drug Evaluation; Eye; Female; Humans; Male; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Sarcoma; Soft Tissue Neoplasms | 1982 |
N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Drug Eruptions; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Soft Tissue Neoplasms | 1982 |
Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Topics: Adult; Aged; Aspartic Acid; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Rectal Neoplasms; Sarcoma | 1983 |
Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
Topics: Adult; Aged; Arthritis; Aspartic Acid; Diarrhea; Drug Eruptions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Psoriasis; Recurrence; Time Factors | 1984 |
PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bone Marrow; Cisplatin; Drug Eruptions; Female; Humans; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Phosphonoacetic Acid; Pilot Projects; Vinblastine; Vindesine; Vomiting | 1984 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Aspartic Acid; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Digestive System; Dose-Response Relationship, Drug; Drug Eruptions; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Phosphonoacetic Acid | 1984 |
Phase II trial of PALA in lymphoma: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Aspartic Acid; Digestive System; Drug Eruptions; Drug Evaluation; Female; Humans; Leukopenia; Lymphoma; Male; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Thrombocytopenia; Thromboembolism | 1984 |
Marked radiosensitization of cells in culture to X ray by 5-chlorodeoxycytidine coadministered with tetrahydrouridine, and inhibitors of pyrimidine biosynthesis.
Topics: Animals; Aspartic Acid; Carcinoma, Squamous Cell; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Radiation; Floxuridine; Humans; Laryngeal Neoplasms; Mice; Organophosphorus Compounds; Phosphonoacetic Acid; Radiation-Sensitizing Agents; Tetrahydrouridine; Uridine | 1984 |
Pyrimidine biosynthesis in Plasmodium berghei.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Chromatography, Gel; Dicarboxylic Acids; Dihydroorotate Oxidase; Hydrogen-Ion Concentration; Kinetics; Ligases; Mice; Oxidoreductases; Phosphonoacetic Acid; Plasmodium berghei; Pyrimidines; Uridine Monophosphate | 1981 |
The cloning and reintroduction into animal cells of a functional CAD gene, a dominant amplifiable genetic marker.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Cloning, Molecular; Cricetinae; Cricetulus; Dihydroorotase; DNA, Recombinant; Drug Resistance; Female; Gene Amplification; Genes, Dominant; Genetic Markers; Genetic Vectors; Multienzyme Complexes; Ovary; Phosphonoacetic Acid; Proteins; Transformation, Genetic; Uridine | 1981 |
Co-amplification of rRNA genes with CAD genes in N-(phosphonacetyl)-L-aspartate-resistant Syrian hamster cells.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Chromosomes; Cricetinae; Dihydroorotase; DNA Restriction Enzymes; Drug Resistance; Gene Amplification; Genes; Mesocricetus; Models, Genetic; Multienzyme Complexes; Nucleic Acid Hybridization; Organophosphorus Compounds; Phosphonoacetic Acid; Proteins; RNA, Ribosomal; Sister Chromatid Exchange | 1983 |
Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells.
Topics: Animals; Aspartic Acid; Bicarbonates; Culture Media; Leukemia L1210; Mice; Phosphonoacetic Acid; Pyrimidines; Sodium Bicarbonate; Uracil Nucleotides; Uridine | 1984 |
Comparison of active mutants and wild-type aspartate transcarbamoylase of Escherichia coli.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Escherichia coli; Kinetics; Macromolecular Substances; Mutation; Phosphonoacetic Acid | 1984 |
The influence of quaternary structure on the active site of an oligomeric enzyme. Catalytic subunit of aspartate transcarbamoylase.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Escherichia coli; Kinetics; Macromolecular Substances; Phosphonoacetic Acid; Spectrophotometry; Trinitrobenzenesulfonic Acid | 1984 |
Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbon Dioxide; Kinetics; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred Strains; Organophosphorus Compounds; Oxygen; Phosphonoacetic Acid; Pyrimidines | 1983 |
Regulatory kinetics of wheat-germ aspartate transcarbamoylase. Adaptation of the concerted model to account for complex kinetic effects of uridine 5'-monophosphate.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Kinetics; Models, Chemical; Phosphonoacetic Acid; Plants; Protein Conformation; Triticum; Uracil Nucleotides; Uridine Monophosphate | 1984 |
Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cell Line; Dose-Response Relationship, Drug; Female; Inosine; Melanoma; Mice; Mice, Inbred C57BL; Nucleosides; Organophosphorus Compounds; Phosphonoacetic Acid; Thioinosine; Thionucleotides | 1984 |
Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Ataxia; Colonic Neoplasms; Confusion; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Middle Aged; Phosphonoacetic Acid; Rectal Neoplasms; Thymidine | 1984 |
A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carmustine; Colonic Neoplasms; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Phosphonoacetic Acid; Rectal Neoplasms | 1984 |
Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carcinoma, Ehrlich Tumor; Kinetics; Mice; Organophosphorus Compounds; Phosphonoacetic Acid; Protein Binding; Tritium | 1984 |
PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aspartic Acid; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Thrombocytopenia; Uterine Cervical Neoplasms | 1984 |
Effect of 12-O-tetradecanoylphorbol-13-acetate on selection of drug-resistant phenotypes in rodent cells.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Cadmium; Cell Line; Cells, Cultured; Clone Cells; Cricetinae; Cricetulus; Drug Resistance; Lung; Methotrexate; Mice; Phenotype; Phorbols; Phosphonoacetic Acid; Tetradecanoylphorbol Acetate; Tetrahydrofolate Dehydrogenase | 1984 |
Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars.
Topics: Animals; Aspartic Acid; Cell Line; Cells, Cultured; Chromatography; Deoxyuracil Nucleotides; Fluorodeoxyuridylate; Fluorouracil; Humans; Melanoma; Mice; Phosphonoacetic Acid; RNA, Neoplasm; Uracil Nucleotides; Uridine; Uridine Triphosphate | 1984 |
Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Drug Therapy, Combination; Female; Fluorouracil; Leucovorin; Male; Methotrexate; Mice; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid; Uridine | 1983 |
Effect of tumor promoter 12-O-tetradecanoylphorbol-13-acetate on recovery of methotrexate-, N-(phosphonacetyl)-L-aspartate-, and cadmium-resistant colony-forming mouse and hamster cells.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Cadmium; Cell Division; Cell Line; Cell Survival; Cells, Cultured; Cricetinae; Cricetulus; Drug Resistance; Kinetics; Lung; Methotrexate; Mice; Organophosphorus Compounds; Phorbols; Phosphonoacetic Acid; Tetradecanoylphorbol Acetate | 1983 |
Structure of amplified DNA in different Syrian hamster cell lines resistant to N-(phosphonacetyl)-L-aspartate.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Cloning, Molecular; Cricetinae; Dihydroorotase; DNA; Drug Resistance; Gene Amplification; Genes; Mesocricetus; Models, Genetic; Multienzyme Complexes; Nucleic Acid Hybridization; Organophosphorus Compounds; Phosphonoacetic Acid; Proteins | 1983 |
Properties of single-step mutants of Syrian hamster cell lines resistant to N-(phosphonacetyl)-L-aspartate.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Cricetinae; Dihydroorotase; Drug Resistance; Gene Amplification; Genes; Mesocricetus; Multienzyme Complexes; Mutation; Nucleic Acid Hybridization; Organophosphorus Compounds; Phosphonoacetic Acid; Proteins | 1983 |
Phase II study of PALA and AMSA in advanced renal cell carcinoma.
Topics: Adenocarcinoma; Aminoacridines; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Drug Evaluation; Drug Therapy, Combination; Humans; Kidney Neoplasms; Phosphonoacetic Acid | 1983 |
Role of endocytosis and lysosomal pH in uptake of N-(phosphonacetyl)-L-aspartate and its inhibition of pyrimidine synthesis.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Carcinoma, Ehrlich Tumor; Endocytosis; Hydrogen-Ion Concentration; Inulin; Kinetics; Lysosomes; Male; Mice; Organophosphorus Compounds; Phosphonoacetic Acid; Pyrimidines; Temperature; Tetradecanoylphorbol Acetate | 1984 |
Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Fluorouracil; Humans; Neoplasms; Nervous System; Phosphonoacetic Acid; Thymidine | 1984 |
A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study.
Topics: Adult; Aged; Aspartic Acid; Blood Cell Count; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Metastasis; Organophosphorus Compounds; Ovarian Neoplasms; Phosphonoacetic Acid; Skin Diseases; Time Factors | 1984 |
Depletion of blood plasma cytidine due to increased hepatocellular salvage in D-galactosamine-treated rats.
Topics: Animals; Antimetabolites; Aspartic Acid; Chromatography, Affinity; Chromatography, High Pressure Liquid; Cytidine; Female; Galactosamine; Liver; Nucleosides; Nucleotides; Phosphonoacetic Acid; Rats; Rats, Inbred Strains; Solubility; Uracil Nucleotides; Uridine Triphosphate | 1984 |
Phase II evaluation of PALA in patients with refractory metastatic sarcomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Bone Neoplasms; Diarrhea; Drug Evaluation; Female; Humans; Male; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Sarcoma; Skin Diseases; Soft Tissue Neoplasms; Stomatitis | 1984 |
Inhibition by N-(phosphonacetyl)-L-aspartate of Ehrlich ascites tumour growth and glucose transport.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Binding Sites; Biological Transport; Carcinoma, Ehrlich Tumor; Cell Division; Cytochalasin B; Dose-Response Relationship, Drug; Glucose; Kinetics; Organophosphorus Compounds; Phosphonoacetic Acid | 1984 |
Quaternary structural changes in aspartate carbamoyltransferase of Escherichia coli at pH 8.3 and pH 5.8.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Escherichia coli; Hydrogen-Ion Concentration; Phosphonoacetic Acid; Protein Conformation; Scattering, Radiation; X-Rays | 1982 |
Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil.
Topics: Animals; Aspartic Acid; Cells, Cultured; Deoxyuracil Nucleotides; Drug Interactions; Fluorodeoxyuridylate; Fluorouracil; Kinetics; Lacticaseibacillus casei; Mice; Organophosphorus Compounds; Phosphonoacetic Acid; Sarcoma 180; Thymidylate Synthase | 1982 |
Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Topics: Adenine Phosphoribosyltransferase; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Ammonia); Drug Resistance; Hypoxanthine Phosphoribosyltransferase; Isoxazoles; Leukemia P388; Leukemia, Experimental; Mice; Mice, Inbred Strains; Organophosphorus Compounds; Oxazoles; Phosphonoacetic Acid; Purines; Pyrimidines | 1983 |
Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Cell Count; Cell Extracts; Cell Line; Cell-Free System; Humans; Kinetics; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid; Time Factors | 1983 |
Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Blood Cell Count; Carcinoma; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Male; Middle Aged; Organophosphorus Compounds; Orotic Acid; Phosphonoacetic Acid; Pyrimidines; Sarcoma | 1983 |
A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
Topics: Alanine; Aspartic Acid; Diarrhea; Digestive System Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Humans; Injections, Intravenous; Organophosphorus Compounds; Phosphonoacetic Acid; Stomatitis | 1983 |
Metabolic resistance: the protection of enzymes against drugs which are tight-binding inhibitors by the accumulation of substrate.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; Drug Resistance; Models, Chemical; Orotidine-5'-Phosphate Decarboxylase; Phosphonoacetic Acid | 1983 |
General method for cloning amplified DNA by differential screening with genomic probes.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Cell Line; Cloning, Molecular; Cricetinae; DNA; DNA, Recombinant; Drug Resistance; Gene Amplification; Gene Expression Regulation; Mesocricetus; Mutation; Nucleic Acid Hybridization; Phosphonoacetic Acid | 1982 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Melanoma; Middle Aged; Neoplasms; Organophosphorus Compounds; Ovarian Neoplasms; Pancreatic Neoplasms; Phosphonoacetic Acid; Sarcoma | 1982 |
Gross quaternary changes in aspartate carbamoyltransferase are induced by the binding of N-(phosphonacetyl)-L-aspartate: A 3.5-A resolution study.
Topics: Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Organophosphorus Compounds; Phosphonoacetic Acid; Protein Binding; Protein Conformation; X-Ray Diffraction | 1982 |
Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Bone Marrow; Cell Line; Cells, Cultured; Cytarabine; DNA Replication; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Organophosphorus Compounds; Phosphonoacetic Acid | 1982 |
Propagation of conformational changes in Ni(II)-substituted aspartate transcarbamoylase: effect of active-site ligands on the regulatory chains.
Topics: Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Cations, Divalent; Escherichia coli; Kinetics; Ligands; Nickel; Phosphonoacetic Acid; Protein Conformation; Spectrum Analysis | 1980 |
Spectral alterations associated with the ligand-promoted gross conformational change in aspartate transcarbamoylase.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Escherichia coli; Macromolecular Substances; Phosphonoacetic Acid; Protein Binding; Protein Conformation; Spectrophotometry, Ultraviolet | 1981 |
Calorimetric estimate of the enthalpy change for the substrate-promoted conformational transition of aspartate transcarbamoylase from Escherichia coli.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Escherichia coli; Phosphonoacetic Acid; Protein Binding; Protein Conformation; Thermodynamics | 1981 |
Changes in the hydrogen exchange kinetics of Escherichia coli aspartate transcarbamylase produced by effector binding and subunit association.
Topics: Adenosine Triphosphate; Aspartate Carbamoyltransferase; Aspartic Acid; Cytidine Triphosphate; Escherichia coli; Hydrogen-Ion Concentration; Kinetics; Macromolecular Substances; Phosphonoacetic Acid; Solvents | 1981 |
Pilot study of PALA and 5-FU in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Cells, Cultured; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; RNA, Neoplasm | 1982 |
Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
Topics: Administration, Oral; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Autoradiography; Biological Availability; Dogs; Feces; Female; Half-Life; Injections, Intravenous; Kinetics; Macaca mulatta; Male; Mice; Mice, Inbred Strains; Organophosphorus Compounds; Phosphonoacetic Acid; Rats; Rats, Inbred Strains; Tissue Distribution | 1982 |
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intravenous; Middle Aged; Organophosphorus Compounds; Pancreatic Neoplasms; Phosphonoacetic Acid; Sarcoma | 1982 |
Relationship between ribo- and deoxyribonucleotide concentrations and biological parameters in cultured Chinese hamster ovary cells.
Topics: Amides; Animals; Aspartic Acid; Cell Cycle; Cells, Cultured; Cricetinae; Cricetulus; Deoxyribonucleotides; Female; Mycophenolic Acid; Ovary; Phosphonoacetic Acid; Pyrazoles; Ribonucleosides; Ribonucleotides; Ribose; Thymidine | 1982 |
Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Isoxazoles; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Nucleic Acids; Organophosphorus Compounds; Orotic Acid; Oxazoles; Phosphonoacetic Acid; Pyrimidines | 1982 |
Ligand-promoted strengthening of interchain bonding domains in catalytic subunits of aspartate transcarbamoylase.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Electrophoresis, Polyacrylamide Gel; Ligands; Macromolecular Substances; Phosphonoacetic Acid; Temperature | 1982 |
Neurotoxicity of the pyrimidine synthesis inhibitor N-phosphonoacetyl-L-aspartate.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Brain Diseases; Disease Models, Animal; Epilepsy; Female; Humans; Male; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Rats; Rats, Inbred Strains; Seizures; Uridine | 1982 |
Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
Topics: Amides; Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Deoxyribonucleotides; DNA Replication; DNA, Neoplasm; Kinetics; Leukemia L1210; Mice; Organophosphorus Compounds; Phosphonoacetic Acid; Pyrazoles; Pyrimidine Nucleotides; Ribonucleosides; Ribonucleotides; Ribose; RNA, Neoplasm; Transcription, Genetic | 1982 |
A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Bone Marrow; Digestive System; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid | 1982 |
Phase II trial of PALA in hypernephroma and urinary bladder cancer.
Topics: Adenocarcinoma; Aspartic Acid; Drug Evaluation; Humans; Kidney Neoplasms; Neoplasm Metastasis; Organophosphorus Compounds; Phosphonoacetic Acid; Urinary Bladder Neoplasms | 1982 |
N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Topics: Adenosine Triphosphate; Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Kinetics; Ligases; Liver Neoplasms, Experimental; Multienzyme Complexes; Organophosphorus Compounds; Phosphonoacetic Acid; Potassium Chloride; Pyrimidines; Rats | 1982 |
Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Topics: Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Drug Evaluation; Humans; Kinetics; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid; Proteins; Pyrimidine Nucleotides; Uridine Triphosphate | 1982 |
PALA in advanced breast cancer. A phase II pilot study by the ECOG.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Bone Marrow; Breast Neoplasms; Digestive System; Drug Evaluation; Female; Humans; Middle Aged; Mucous Membrane; Organophosphorus Compounds; Phosphonoacetic Acid; Skin; United States | 1982 |
Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
Topics: Antineoplastic Agents; Aspartic Acid; Chromatography, High Pressure Liquid; Drug Evaluation; Humans; Infusions, Parenteral; Kinetics; Organophosphorus Compounds; Phosphonoacetic Acid; Tears | 1981 |
Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography.
Topics: Aspartic Acid; Chromatography, High Pressure Liquid; Humans; Organophosphorus Compounds; Phosphonoacetic Acid | 1980 |
Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. I. Embryolethal, teratogenic, and cytogenetic effects.
Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents; Aspartic Acid; Chromosomes, Human; Dose-Response Relationship, Drug; Female; Fetal Death; Gestational Age; Humans; Lymphocytes; Mice; Mitosis; Mutagens; Organophosphorus Compounds; Phosphonoacetic Acid; Pregnancy; Teratogens | 1980 |
Salvage of circulating pyrimidine nucleosides in the rat.
Topics: Amides; Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Cytidine; Male; Phosphonoacetic Acid; Pyrazoles; Pyrimidine Nucleosides; Pyrimidine Nucleotides; Rats; Ribonucleosides; Ribose; Tissue Distribution; Uridine | 1981 |
Uptake of 14C-labeled dicarboxylic amino acids in hepatocytes and hepatoma cells.
Topics: Alanine; Amino Acids; Amino Acids, Cyclic; Amino Acids, Dicarboxylic; Aminoisobutyric Acids; Animals; Antibiotics, Antineoplastic; Aspartic Acid; Liver; Liver Neoplasms, Experimental; Male; Nitrosamines; Phosphonoacetic Acid; Rats; Sodium | 1981 |
Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid.
Topics: Animals; Aspartic Acid; Cells, Cultured; Chromatography, High Pressure Liquid; Deoxycytosine Nucleotides; Deoxyribonucleosides; Drug Synergism; Glycine; Isoxazoles; Leukemia L1210; Mice; Organophosphorus Compounds; Orotic Acid; Oxazoles; Phosphonoacetic Acid; Pyrimidines; Ribonucleosides | 1981 |
Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Cell Division; Cell Line; Humans; Leukemia; Melanoma; Mice; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid | 1981 |
De novo pyrimidine nucleotide synthesis in the preimplantation mouse embryo.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Blastocyst; Mice; Morula; Orotic Acid; Phosphonoacetic Acid; Pyrimidine Nucleotides; Uridine | 1981 |
Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
Topics: Antineoplastic Agents; Aspartic Acid; Breast Neoplasms; Cell Division; Cell Line; Drug Synergism; Female; Fluorouracil; Humans; Organophosphorus Compounds; Phosphonoacetic Acid; Poly A; RNA, Neoplasm; Uridine Triphosphate | 1981 |
Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Creatinine; Drug Evaluation; Humans; Metabolic Clearance Rate; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid; Tissue Distribution | 1980 |
Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Drug Evaluation; Humans; Kinetics; Metabolic Clearance Rate; Organophosphorus Compounds; Phosphonoacetic Acid; Protein Binding | 1980 |
Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
Topics: Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Gas Chromatography-Mass Spectrometry; Humans; Hydrolysis; Mass Spectrometry; Organophosphorus Compounds; Phosphonoacetic Acid | 1980 |
Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
Topics: Antineoplastic Agents; Aspartic Acid; Gas Chromatography-Mass Spectrometry; Humans; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid | 1980 |
Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Colonic Neoplasms; Drug Evaluation; Humans; Melanoma; Organophosphorus Compounds; Phosphonoacetic Acid; Uridine | 1980 |
Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
Topics: Aspartic Acid; Brain Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Parenteral; Nervous System Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid; Time Factors | 1980 |
An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Drug Evaluation; Humans; Kinetics; Neoplasms, Experimental; Organophosphorus Compounds; Phosphonoacetic Acid | 1980 |
N-(Phosphonacetyl)-L-aspartate (PALA): current status.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Drug Evaluation; Humans; Mice; Neoplasms, Experimental; Phosphonoacetic Acid | 1980 |
Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Bone and Bones; Dialysis; Dose-Response Relationship, Drug; Kidney; Male; Mice; Organophosphorus Compounds; Phosphonoacetic Acid; Tissue Distribution | 1981 |
Biochemical and antitumor effects of the combination of thymidine and 1-beta-D-arabinofuranosylcytosine against leukemia L1210.
Topics: Animals; Arabinofuranosylcytosine Triphosphate; Aspartic Acid; Cells, Cultured; Cytarabine; Cytidine; Drug Therapy, Combination; Leukemia L1210; Mice; Phosphonoacetic Acid; Thymidine | 1981 |
Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Topics: Amides; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carcinoma; Cell Line; Dose-Response Relationship, Drug; Drug Resistance; Lung Neoplasms; Mice; Neoplasms, Experimental; Orotic Acid; Phosphonoacetic Acid; Pyrazoles; Pyrimidines; Ribonucleosides; Ribose | 1981 |
Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Carcinoma; Drug Therapy, Combination; Glycine; Isoxazoles; Ligases; Lung Neoplasms; Neoplasms, Experimental; Organophosphorus Compounds; Oxazoles; Phosphonoacetic Acid; Pyrimidines; Rats | 1981 |
Phase I trial of PALA.
Topics: Antineoplastic Agents; Aspartic Acid; Brain Diseases; Diarrhea; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Leukocyte Count; Neoplasms; Organophosphorus Compounds; Phosphonoacetic Acid; Platelet Count; Seizures; Skin Diseases | 1980 |
Evaluation of the antiviral activity of N-(phosphonoacetyl)-L-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats.
Topics: Animals; Antiviral Agents; Aspartic Acid; Chlorocebus aethiops; Dogs; Evaluation Studies as Topic; Female; Male; Measles virus; Molecular Structure; Parainfluenza Virus 3, Human; Phosphonoacetic Acid; Rats; Respiratory Syncytial Viruses; Respirovirus; Sigmodontinae; Toxicity Tests; Tumor Cells, Cultured; Vero Cells | 1995 |
The propensity for gene amplification: a comparison of protocols, cell lines, and selection agents.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line, Transformed; CHO Cells; Cricetinae; Demecolcine; Dihydroorotase; Dose-Response Relationship, Drug; Drug Resistance; Fibroblasts; Folic Acid Antagonists; Gene Amplification; HeLa Cells; Humans; Lethal Dose 50; Methotrexate; Multienzyme Complexes; Phosphonoacetic Acid; Research Design; RNA, Messenger; Tetrahydrofolate Dehydrogenase; Trimetrexate | 1994 |
p53 expression in normal versus transformed mammalian cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Aspartic Acid; Burkitt Lymphoma; Cell Line; Cell Transformation, Neoplastic; Cells, Cultured; CHO Cells; Cholera Toxin; Cricetinae; Drug Resistance; Embryo, Mammalian; Gene Expression; Genes, p53; Humans; Immunohistochemistry; L Cells; Lymphocytes; Methotrexate; Mice; Phosphonoacetic Acid; Reference Values; Theophylline; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1995 |
Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation.
Topics: Adenocarcinoma; Animals; Aspartic Acid; Body Weight; Deoxycytidine; Idoxuridine; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Phosphonoacetic Acid; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tetrahydrouridine | 1995 |
X-ray scattering titration of the quaternary structure transition of aspartate transcarbamylase with a bisubstrate analogue: influence of nucleotide effectors.
Topics: Adenosine Triphosphate; Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Cytidine Triphosphate; Models, Chemical; Nucleotides; Phosphonoacetic Acid; Protein Conformation; Scattering, Radiation; X-Rays | 1995 |
Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Female; Floxuridine; Mice; Mice, Inbred BALB C; Phosphonoacetic Acid; Tumor Cells, Cultured | 1995 |
DNA topoisomerase II inhibition and gene amplification in V79/B7 cells.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Benzamides; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cells, Cultured; Chromosome Aberrations; Cricetinae; Cricetulus; Dihydroorotase; DNA Damage; DNA Repair; Drug Resistance; Etoposide; Gene Amplification; Multienzyme Complexes; Phosphonoacetic Acid; Topoisomerase II Inhibitors | 1993 |
Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors.
Topics: Aspartic Acid; Biphenyl Compounds; Calcimycin; Cells, Cultured; Cyclosporine; Humans; Immunosuppressive Agents; Interleukin-2; Lymphocyte Activation; Lymphocytes; Mycophenolic Acid; Phosphonoacetic Acid; Ribonucleosides; T-Lymphocytes; Tacrolimus; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1993 |
Glu-50 in the catalytic chain of Escherichia coli aspartate transcarbamoylase plays a crucial role in the stability of the R quaternary structure.
Topics: Alanine; Allosteric Regulation; Allosteric Site; Aspartate Carbamoyltransferase; Aspartic Acid; Enzyme Activation; Enzyme Stability; Escherichia coli; Glutamic Acid; Kinetics; Nucleotides; Phosphonoacetic Acid; Point Mutation; Protein Conformation; Scattering, Radiation; Succinates; Succinic Acid; X-Rays | 1994 |
Drug resistance and gene amplification potential regulated by transforming growth factor beta 1 gene expression.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Blotting, Southern; Cell Division; Cell Line; Drug Resistance; Gene Amplification; Gene Expression; Mice; Phosphonoacetic Acid; Recombinant Proteins; Swine; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1995 |
p53-dependent growth arrest of REF52 cells containing newly amplified DNA.
Topics: Animals; Antigens, Viral, Tumor; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; Cell Cycle; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dihydroorotase; DNA Damage; DNA Replication; Drug Resistance; Gene Amplification; Hot Temperature; In Situ Hybridization, Fluorescence; Ligases; Mutation; Phosphonoacetic Acid; Rats; Recombinant Proteins; RNA, Messenger; Selection, Genetic; Simian virus 40; Tumor Suppressor Protein p53 | 1995 |
Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis.
Topics: Animals; Apoptosis; Aspartic Acid; Carrier Proteins; Cell Cycle Proteins; Cell Nucleus; Cells, Cultured; DNA-Binding Proteins; E2F Transcription Factors; Genes, p53; Genes, Retinoblastoma; Methotrexate; Mice; Phosphonoacetic Acid; Retinoblastoma Protein; Retinoblastoma-Binding Protein 1; S Phase; Transcription Factor DP1; Transcription Factors | 1995 |
Gene amplification in Chinese hamster DNA repair deficient mutants.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); CHO Cells; Cricetinae; Dihydroorotase; DNA Repair; Drug Resistance; Gene Amplification; Multienzyme Complexes; Mutagenesis; Phosphonoacetic Acid; Radiation Tolerance; Ultraviolet Rays | 1995 |
Telomeric and nontelomeric (TTAGGG)n sequences in gene amplification and chromosome stability.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cells, Cultured; CHO Cells; Cricetinae; Dihydroorotase; DNA Primers; Drug Resistance; Fibroblasts; Gene Amplification; In Situ Hybridization, Fluorescence; Multienzyme Complexes; Mutation; Phosphonoacetic Acid; Telomere | 1994 |
Gene amplification and gene deletion are induced at different rates in V79/AP4 Chinese hamster cells.
Topics: 2-Aminopurine; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Division; Cell Line; Cricetinae; Cricetulus; Dihydroorotase; DNA; DNA Replication; Drug Resistance; Gene Amplification; Gene Deletion; Mitomycin; Multienzyme Complexes; Mutagenesis; Mutagens; Phosphonoacetic Acid | 1993 |
Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Blotting, Southern; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Dihydroorotase; DNA; Drug Resistance; Fibroblast Growth Factor 2; Fibroblast Growth Factor 4; Fibroblast Growth Factors; Fibroblasts; Gene Amplification; Hydroxyurea; Methotrexate; Mice; Multienzyme Complexes; Phosphonoacetic Acid; Proto-Oncogene Proteins; Ribonucleotide Reductases; Suramin; Tetrahydrofolate Dehydrogenase; Transfection | 1994 |
Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins.
Topics: Antineoplastic Agents; Aspartic Acid; Cell Cycle; Fibroblasts; Gene Amplification; Genetic Vectors; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Oncogene Proteins, Viral; Open Reading Frames; Papillomaviridae; Phosphonoacetic Acid; Recombinant Proteins; Transfection; Tumor Suppressor Protein p53 | 1994 |
Glutamic acid 86 is important for positioning the 80's loop and arginine 54 at the active site of Escherichia coli aspartate transcarbamoylase and for the structural stabilization of the C1-C2 interface.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Enzyme Stability; Escherichia coli; Glutamic Acid; Kinetics; Mutagenesis, Site-Directed; Phosphonoacetic Acid; Structure-Activity Relationship | 1994 |
Structural modeling and electrostatic properties of aspartate transcarbamylase from Saccharomyces cerevisiae.
Topics: Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Computer Simulation; Electricity; Escherichia coli; Evaluation Studies as Topic; Ions; Models, Molecular; Molecular Sequence Data; Phosphonoacetic Acid; Protein Conformation; Saccharomyces cerevisiae; Sequence Alignment; Sequence Homology, Amino Acid | 1994 |
Loss of chromosomal integrity in neoplasia.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Chromosome Aberrations; Dihydroorotase; Drug Resistance; Gene Amplification; Humans; Models, Genetic; Multienzyme Complexes; Neoplasms; Oncogenes; Phosphonoacetic Acid; Tumor Cells, Cultured | 1993 |
Ligation alters the pathway of urea-induced denaturation of the catalytic trimer of Escherichia coli aspartate transcarbamylase.
Topics: Adenosine Triphosphate; Anions; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Catalysis; Chemical Phenomena; Chemistry, Physical; Chlorides; Escherichia coli; Macromolecular Substances; Phosphonoacetic Acid; Protein Denaturation; Protein Folding; Spectrophotometry; Thermodynamics; Urea | 1994 |
Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy.
Topics: Animals; Aspartic Acid; Colonic Neoplasms; Female; Fluorine; Fluorouracil; Interferon-alpha; Leucovorin; Magnetic Resonance Spectroscopy; Methotrexate; Mice; Mice, Inbred C57BL; Phosphonoacetic Acid; Rats; Tumor Cells, Cultured | 1994 |
Aberrant expression of basic fibroblast growth factor in NIH-3T3 cells alters drug resistance and gene amplification potential.
Topics: 3T3 Cells; Animals; Aspartic Acid; Drug Resistance; Fibroblast Growth Factor 2; Gene Amplification; Mice; Phosphonoacetic Acid; Transfection | 1994 |
Depletion of nuclear poly(ADP-ribose) polymerase by antisense RNA expression: influences on genomic stability, chromatin organization, and carcinogen cytotoxicity.
Topics: Aspartic Acid; Carbamoyl-Phosphate Synthase (Ammonia); Cell Survival; Chromatin; Dexamethasone; DNA Repair; Gene Amplification; HeLa Cells; Humans; Methyl Methanesulfonate; Phosphonoacetic Acid; Poly(ADP-ribose) Polymerases; RNA, Antisense; RNA, Messenger; Tumor Stem Cell Assay | 1994 |
A 70-amino acid zinc-binding polypeptide fragment from the regulatory chain of aspartate transcarbamoylase causes marked changes in the kinetic mechanism of the catalytic trimer.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Carbamyl Phosphate; Carbon Isotopes; Catalysis; Escherichia coli; Hydrogen-Ion Concentration; Kinetics; Macromolecular Substances; Peptide Fragments; Phosphonoacetic Acid; Structure-Activity Relationship; Succinates; Succinic Acid; Zinc | 1994 |
The enhancement of the frequency of resistance to N-phosphonoacetyl-L-aspartate and methotrexate by 1-beta-D-arabinofuranosylcytosine: the effect of dipyridamole.
Topics: Animals; Aspartic Acid; Cell Line, Transformed; Cricetinae; Cytarabine; Dipyridamole; Drug Resistance; Drug Synergism; Humans; Methotrexate; Nucleosides; Phosphonoacetic Acid; Thioinosine | 1994 |
Accumulation of anchorage independent cells showing amplified genes (CAD) during the in vitro propagation of CHEF18 Chinese hamster cells.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Adhesion; Cell Line; Cell Transformation, Neoplastic; Cricetinae; Dihydroorotase; Drug Resistance; Gene Amplification; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Phosphonoacetic Acid; Thioguanine | 1993 |
5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Drug Synergism; Female; Fluorouracil; Leucovorin; Neoplasm Transplantation; Phosphonoacetic Acid; Rats; Rats, Inbred F344; Uracil | 1994 |
Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Aspartic Acid; Cell Transformation, Neoplastic; Drug Resistance; Gene Amplification; Gene Expression Regulation, Neoplastic; Genes, ras; Isopropyl Thiogalactoside; Methotrexate; Mice; Phosphonoacetic Acid; Tetrahydrofolate Dehydrogenase | 1994 |
Biochemical modulation of tumor cell energy in vivo: II. A lower dose of adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed.
Topics: 6-Aminonicotinamide; Animals; Apoptosis; Aspartic Acid; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Energy Metabolism; Mammary Neoplasms, Experimental; Methylthioinosine; Phosphonoacetic Acid | 1994 |
The effects of various inhibitors on the regulation of orotic acid excretion in sparse-fur mutant mice (spf/Y) deficient in ornithine transcarbamylase.
Topics: Adenine; Animals; Antimetabolites; Aspartic Acid; Creatinine; Cycloheximide; Injections, Intraperitoneal; Isoxazoles; Liver; Male; Mice; Mice, Mutant Strains; Ornithine; Ornithine Carbamoyltransferase Deficiency Disease; Orotic Acid; Phosphonoacetic Acid | 1993 |
Differential expression of transporters for norepinephrine and glutamate in wild type, variant, and WNT1-expressing PC12 cells.
Topics: Alanine; Amino Acid Sequence; Amino Acid Transport System X-AG; Animals; Aspartic Acid; Biological Transport; Carrier Proteins; DNA, Complementary; Gene Expression; Glycine; Glycoproteins; Molecular Sequence Data; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oncogene Proteins; PC12 Cells; Phosphonoacetic Acid; RNA, Messenger; Symporters | 1993 |
N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Aspartic Acid; Base Sequence; Cell Division; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Drug Synergism; Fluorouracil; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Nucleotides; Oligodeoxyribonucleotides; Phosphonoacetic Acid; Recombinant Proteins; RNA, Neoplasm; Tumor Cells, Cultured | 1993 |
Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
Topics: Antineoplastic Agents; Aspartic Acid; Cell Division; Drug Carriers; Drug Compounding; Female; Humans; Liposomes; Ovarian Neoplasms; Phosphonoacetic Acid; Surface Properties; Tumor Cells, Cultured | 1993 |
Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography.
Topics: Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Chromatography, High Pressure Liquid; Cytosol; Enzyme Activation; Erythrocytes; Humans; Hydrolysis; Leukocytes, Mononuclear; Phosphonoacetic Acid | 1993 |
Reconstitution of active catalytic trimer of aspartate transcarbamoylase from proteolytically cleaved polypeptide chains.
Topics: Allosteric Site; Aspartate Carbamoyltransferase; Aspartic Acid; Chymotrypsin; Enzyme Stability; Escherichia coli; Kinetics; Models, Molecular; Peptide Fragments; Phosphonoacetic Acid; Protein Conformation; Substrate Specificity; X-Ray Diffraction | 1993 |
Amplification potential in preneoplastic and neoplastic Syrian hamster embryo fibroblasts transformed by various carcinogens.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Carcinogens; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cricetinae; DNA, Neoplasm; Drug Resistance; Embryo, Mammalian; Fibroblasts; Fibrosarcoma; Gene Amplification; In Situ Hybridization, Fluorescence; Mesocricetus; Mice; Mice, Inbred BALB C; Mice, Nude; Oncogenes; Phosphonoacetic Acid; Precancerous Conditions; Transfection; Tumor Cells, Cultured | 1993 |
Potentiation of a three drug chemotherapy regimen by radiation.
Topics: 6-Aminonicotinamide; Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Combined Modality Therapy; Female; Mercaptopurine; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Phosphonoacetic Acid | 1993 |
Sequence of the novel joints present in the amplified DNA of N-phosphonacetyl-L-aspartate resistant Drosophila cells: implication on the mechanisms of amplification in these cells.
Topics: Animals; Aspartic Acid; Base Sequence; Cloning, Molecular; DNA; Drosophila melanogaster; Drug Resistance; Gene Amplification; Molecular Sequence Data; Phosphonoacetic Acid; Reference Values; Sequence Homology, Nucleic Acid | 1993 |
Multiple mechanisms of N-(phosphonoacetyl)-L-aspartate drug resistance in SV40-infected precrisis human fibroblasts.
Topics: Aneuploidy; Antineoplastic Agents; Aspartic Acid; Cell Cycle; Cell Division; Cell Line; Cell Transformation, Viral; Chromosome Aberrations; Chromosomes, Human, Pair 2; Clone Cells; Drug Resistance; Fibroblasts; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Phosphonoacetic Acid; Simian virus 40 | 1993 |
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Topics: Adenocarcinoma; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Immunity, Cellular; Immunosuppressive Agents; Interleukin-2; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocytes; Monocytes; Phenotype; Phosphonoacetic Acid | 1993 |
Peptide-protein interaction markedly alters the functional properties of the catalytic subunit of aspartate transcarbamoylase.
Topics: Allosteric Regulation; Allosteric Site; Aspartate Carbamoyltransferase; Aspartic Acid; Escherichia coli; Kinetics; Mutagenesis, Site-Directed; Phosphonoacetic Acid; Protein Conformation; Thermodynamics; Zinc | 1993 |
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Drug Synergism; Female; Fluorouracil; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Mouth Mucosa; Neoplasms; Phosphonoacetic Acid; Stomatitis; Uridine | 1993 |
Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Cytidine Triphosphate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Infusions, Intravenous; Leukemia L1210; Mice; Mice, Inbred BALB C; Phosphonoacetic Acid; Uridine Triphosphate | 1993 |
Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Dietary Proteins; Intestinal Mucosa; Intestines; Liver; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Phosphonoacetic Acid; Pyrimidines | 1993 |
Tumorigenicity and gene amplification potentials of cyclin D1-overexpressing NIH3T3 cells.
Topics: 3T3 Cells; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Adhesion; Cell Transformation, Neoplastic; Cyclin D1; Cyclins; Dihydroorotase; Gene Amplification; Humans; Mice; Multienzyme Complexes; Neoplasms, Experimental; Oncogene Proteins; Phosphonoacetic Acid; Transfection | 1995 |
PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartic Acid; Bromodeoxyuridine; Cell Division; DNA, Neoplasm; Female; Humans; Nucleotides; Ovarian Neoplasms; Phosphonoacetic Acid; Time Factors; Tumor Stem Cell Assay | 1996 |
A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage.
Topics: Adenosine Monophosphate; Amides; Antimetabolites, Antineoplastic; Aspartic Acid; Cell Cycle; Cells, Cultured; Chromosome Aberrations; DNA Damage; Gamma Rays; Humans; Male; Phosphonoacetic Acid; Pyrazoles; Ribonucleosides; Ribonucleotides; Ribose; RNA; Tumor Suppressor Protein p53 | 1996 |
Biochemical modulation of tumor cell energy. IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression.
Topics: 6-Aminonicotinamide; Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aspartic Acid; Doxorubicin; Mammary Neoplasms, Animal; Methylthioinosine; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Phosphonoacetic Acid; Time Factors | 1995 |
Correlation of retention of tumor methylmercaptopurine riboside-5'-phosphate with effectiveness in CD8F1 murine mammary tumor regression.
Topics: 6-Aminonicotinamide; Adenosine Kinase; Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Mammary Neoplasms, Experimental; Methylthioinosine; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Phosphonoacetic Acid | 1996 |
Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Aspartic Acid; Cytarabine; Cytidine Triphosphate; DNA, Neoplasm; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Leukemia; Phosphonoacetic Acid; Tumor Cells, Cultured; Uridine Triphosphate | 1996 |
Human chromosome 3 mediates growth arrest and suppression of apoptosis in microcell hybrids.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Aspartic Acid; Cell Cycle; Cesium Radioisotopes; Chromosome Mapping; Chromosomes, Human, Pair 3; Fibroblasts; Flow Cytometry; G1 Phase; G2 Phase; Gamma Rays; Genetic Markers; Humans; Hybrid Cells; In Situ Hybridization, Fluorescence; Melanoma, Experimental; Mice; Phosphonoacetic Acid; Tumor Cells, Cultured | 1996 |
Cytosine deaminase gene as a positive selection marker.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Apoptosis; Aspartic Acid; Cell Cycle; Cell Division; Cell Line, Transformed; Cell Survival; Culture Media; Cytosine; Cytosine Deaminase; Flucytosine; Gene Expression; Genes, Bacterial; Genetic Markers; Inosine; Mice; Nucleoside Deaminases; Phosphonoacetic Acid; Rats; Transfection; Tumor Cells, Cultured | 1996 |
p53-dependent cell cycle arrests are preserved in DNA-activated protein kinase-deficient mouse fibroblasts.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Base Sequence; Cell Cycle; Cells, Cultured; DNA Damage; DNA-Activated Protein Kinase; DNA-Binding Proteins; Embryo, Mammalian; Female; Fibroblasts; G1 Phase; Male; Mice; Mice, Knockout; Mice, SCID; Micronuclei, Chromosome-Defective; Molecular Sequence Data; Phosphonoacetic Acid; Protein Serine-Threonine Kinases; Ribonucleotides; Spindle Apparatus; Tumor Suppressor Protein p53 | 1996 |
Influence of both salvage and DNA damage response pathways on resistance to chemotherapeutic antimetabolites.
Topics: Antimetabolites; Aspartic Acid; Cell Survival; DNA; Dose-Response Relationship, Drug; Drug Resistance; Fibroblasts; Humans; Methotrexate; Phosphonoacetic Acid; Tumor Cells, Cultured | 1996 |
Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb.
Topics: Animals; Aspartic Acid; Cells, Cultured; G1 Phase; Gene Amplification; Genes, p53; Genes, Retinoblastoma; Mice; Phosphonoacetic Acid; Transforming Growth Factor beta | 1996 |
Separate pathways for p53 induction by ionizing radiation and N-(phosphonoacetyl)-L-aspartate.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Base Sequence; Cell Cycle; Cell Line; DNA Damage; Gene Expression Regulation; Genes, p53; Humans; Molecular Sequence Data; Phosphonoacetic Acid; Tumor Suppressor Protein p53 | 1996 |
Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
Topics: Amides; Antineoplastic Agents; Aspartic Acid; Blotting, Western; Breast Neoplasms; Cell Cycle; Clone Cells; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Flow Cytometry; Gene Expression; Genes, p53; Humans; Immunohistochemistry; Melphalan; Mitoxantrone; Neoplasm Proteins; Nuclear Proteins; Phosphonoacetic Acid; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazoles; Ribonucleosides; Ribose; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1996 |
Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Doxorubicin; Fluorouracil; Mammary Neoplasms, Animal; Mercaptopurine; Mice; Niacinamide; Phosphonoacetic Acid | 1996 |
Protein alterations associated with gene amplification in cultured human and rodent cells.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carcinoma, Hepatocellular; Cell Division; CHO Cells; Cricetinae; Dihydroorotase; Drug Resistance; Electrophoresis, Gel, Two-Dimensional; Gene Amplification; Growth Inhibitors; Humans; Infant; Ligases; Liver Neoplasms; Phosphonoacetic Acid; Proteins; RNA, Messenger; Silver Staining; Tumor Cells, Cultured | 1996 |
Inefficient growth arrest in response to dNTP starvation stimulates gene amplification through bridge-breakage-fusion cycles.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Cell Division; Cell Line; Cloning, Molecular; Cricetinae; DNA Damage; Fluorouracil; Gene Amplification; Growth Inhibitors; Humans; In Situ Hybridization, Fluorescence; Methotrexate; Phosphonoacetic Acid; Pyrimidine Nucleotides; Tumor Cells, Cultured | 1996 |
In vivo detection by 31P NMR of pentose phosphate pathway block secondary to biochemical modulation.
Topics: 6-Aminonicotinamide; Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cell Division; Magnetic Resonance Spectroscopy; Male; Mammary Neoplasms, Experimental; Methylthioinosine; Mice; Mice, Inbred C3H; Pentose Phosphate Pathway; Phosphonoacetic Acid; Phosphorus; Teratogens | 1996 |
Marked enhancement in vivo of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation.
Topics: 6-Aminonicotinamide; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Mammary Neoplasms, Experimental; Methylthioinosine; Mice; Paclitaxel; Phosphonoacetic Acid; Remission Induction | 1996 |
The allosteric activator ATP induces a substrate-dependent alteration of the quaternary structure of a mutant aspartate transcarbamoylase impaired in active site closure.
Topics: Adenosine Triphosphate; Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Kinetics; Mutagenesis, Site-Directed; Phosphonoacetic Acid; Protein Conformation; Scattering, Radiation; Succinates; Succinic Acid | 1996 |
Engineered complementation in Escherichia coli aspartate transcarbamoylase. Heterotropic regulation by quaternary structure stabilization.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Enzyme Activation; Escherichia coli; Genetic Complementation Test; Mutagenesis; Phosphonoacetic Acid; Protein Conformation; Recombinant Proteins | 1996 |
Multiple mechanisms of N-phosphonacetyl-L-aspartate resistance in human cell lines: carbamyl-P synthetase/aspartate transcarbamylase/dihydro-orotase gene amplification is frequent only when chromosome 2 is rearranged.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Centromere; Chromosome Aberrations; Chromosomes, Human, Pair 2; Dihydroorotase; DNA Probes; Drug Resistance; Gene Amplification; Gene Dosage; Gene Expression; Humans; In Situ Hybridization, Fluorescence; Multienzyme Complexes; Phosphonoacetic Acid; Telomere; Tumor Cells, Cultured | 1997 |
Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade.
Topics: 6-Aminonicotinamide; Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aspartic Acid; DNA Damage; Humans; Mercaptopurine; Mice; Phosphonoacetic Acid; Poly(ADP-ribose) Polymerases | 1997 |
Evidence that resistance to osmotic stress is mediated by gene amplification.
Topics: Animals; Aspartic Acid; Cells, Cultured; Cricetinae; Cricetulus; Gene Amplification; Phosphonoacetic Acid; Water-Electrolyte Balance | 1997 |
Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion.
Topics: 6-Aminonicotinamide; Adenosine Triphosphate; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aspartic Acid; Female; Mammary Neoplasms, Experimental; Mercaptopurine; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Phosphonoacetic Acid; Time Factors | 1997 |
Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase.
Topics: Animals; Aspartic Acid; Cell Division; Cell Survival; Cells, Cultured; DNA Damage; Embryo, Mammalian; Fibroblasts; G1 Phase; Growth Inhibitors; Mice; Mice, Knockout; Phosphonoacetic Acid; Poly(ADP-ribose) Polymerases; Transcription, Genetic; Tumor Suppressor Protein p53 | 1997 |
A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2'-deoxyuridine.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Cell Death; Cell Line; Cricetinae; Cytarabine; DNA; DNA Topoisomerases, Type II; Drug Resistance; Drug Synergism; Enzyme Induction; Etoposide; Floxuridine; Gene Amplification; Humans; Kidney; Phosphonoacetic Acid | 1997 |
Inhibition of vaccinia virus replication by N-(phosphonoacetyl)-L-aspartate: differential effects on viral gene expression result from a reduced pyrimidine nucleotide pool.
Topics: Antiviral Agents; Aspartic Acid; Cell Survival; Cytidine Triphosphate; DNA-Directed RNA Polymerases; Gene Expression Regulation, Viral; HeLa Cells; Humans; Kinetics; Macromolecular Substances; Phosphonoacetic Acid; Pyrimidine Nucleotides; RNA, Messenger; Transcription, Genetic; Uridine; Uridine Triphosphate; Vaccinia virus; Virus Replication | 1997 |
Identification of additional complementation groups that regulate genomic instability.
Topics: Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Cycle; Dihydroorotase; Drug Resistance, Neoplasm; Fibroblasts; Gene Amplification; Genes, p53; Genes, Recessive; Genetic Complementation Test; Humans; Hybrid Cells; Multienzyme Complexes; Phosphonoacetic Acid; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1997 |
In situ properties of Helicobacter pylori aspartate carbamoyltransferase.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; Cytidine Triphosphate; Enzyme Inhibitors; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Kinetics; Magnetic Resonance Spectroscopy; Maleates; Organophosphates; Phosphonoacetic Acid; Ribose; Stereoisomerism; Substrate Specificity; Succinic Acid; Temperature | 1997 |
Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Antisense Elements (Genetics); Aspartic Acid; Drug Resistance, Neoplasm; Gene Amplification; Gene Expression Regulation, Enzymologic; Genes, p53; Genetic Vectors; Hydroxyurea; L Cells; Methotrexate; Mice; Phosphonoacetic Acid; Retroviridae; Ribonucleotide Reductases; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 1997 |
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Pancreatic Neoplasms; Phosphonoacetic Acid | 1997 |
MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Cycle; Dihydroorotase; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, myc; Multienzyme Complexes; Phosphonoacetic Acid; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage.
Topics: Antimetabolites; Apoptosis; Aspartic Acid; Cell Cycle; Cell Differentiation; Cell Nucleus; DNA Damage; Doxorubicin; Embryo, Mammalian; Gamma Rays; Humans; Phosphonoacetic Acid; Stem Cells; Transfection; Tretinoin; Tumor Suppressor Protein p53 | 1998 |
Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage.
Topics: Aspartic Acid; Cell Cycle; Cell Cycle Proteins; DNA Damage; Drug Resistance; Fibrosarcoma; Gene Amplification; Humans; Methotrexate; Models, Genetic; Nucleotides; Phosphonoacetic Acid; Selection, Genetic; Skin Neoplasms; Tetrahydrofolate Dehydrogenase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
CAD overexpression in mammalian cells.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Division; Cell Line; Cloning, Molecular; Cricetinae; Dihydroorotase; Molecular Sequence Data; Multienzyme Complexes; Phosphonoacetic Acid; Recombinant Proteins; Transfection; Uridine | 1998 |
Effects of the T-->R transition on the electrostatic properties of E. coli aspartate transcarbamylase.
Topics: Allosteric Regulation; Allosteric Site; Aspartate Carbamoyltransferase; Aspartic Acid; Cytidine Triphosphate; Databases, Factual; Escherichia coli; Hydrogen-Ion Concentration; Isoelectric Point; Malonates; Phosphonoacetic Acid; Protein Conformation; Statistical Distributions; Thermodynamics | 1998 |
Cellular responses in mouse leukemia L1210 cells made resistant to deoxyadenosine.
Topics: Animals; Apoptosis; Aspartic Acid; Deoxyadenine Nucleotides; Deoxyadenosines; Drug Resistance; Guanosine Triphosphate; Isoxazoles; Leukemia L1210; Mice; Nucleotides; Phosphonoacetic Acid; Ribonucleotide Reductases; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
A novel mechanism for resistance to the antimetabolite N-phosphonoacetyl-L-aspartate by Helicobacter pylori.
Topics: Antimetabolites; Aspartic Acid; Biological Transport; Drug Resistance, Microbial; Growth Inhibitors; Helicobacter pylori; Kinetics; Metals; Phosphonoacetic Acid; Temperature; Tritium | 1998 |
Effects of nucleic acid inhibitors on the development of Angiostrongylus costaricensis in vitro.
Topics: Aminopterin; Angiostrongylus; Animals; Aspartic Acid; Azaguanine; Growth Inhibitors; Larva; Nucleic Acid Synthesis Inhibitors; Nucleic Acids; Phosphonoacetic Acid | 1998 |
Correlation of genetic instability and apoptosis in the presence of oncogenic Ki-Ras.
Topics: 3T3 Cells; Animals; Apoptosis; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Colony-Forming Units Assay; Culture Media, Serum-Free; Dihydroorotase; DNA Repair; G1 Phase; GADD45 Proteins; Gene Amplification; Gene Expression; Genes, p53; Genes, ras; Intracellular Signaling Peptides and Proteins; Mice; Multienzyme Complexes; Nuclear Proteins; Phosphonoacetic Acid; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Signal Transduction | 1998 |
Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype.
Topics: Aspartic Acid; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p16; DNA-Binding Proteins; Enzyme Inhibitors; Humans; Hydroxyurea; Nucleic Acid Synthesis Inhibitors; Phenotype; Phosphonoacetic Acid; Phosphorylation; Protein Biosynthesis; Proteins; Retinoblastoma Protein; RNA; Telomerase; Tumor Cells, Cultured | 1999 |
p53 inhibits entry into mitosis when DNA synthesis is blocked.
Topics: Animals; Aspartic Acid; Cell Line, Transformed; Chromatin; DNA Replication; Histones; Humans; Hydroxyurea; Mice; Mitosis; Phosphonoacetic Acid; Phosphorylation; Spindle Apparatus; Tumor Suppressor Protein p53 | 1999 |
Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers.
Topics: Aspartic Acid; Chromosome Aberrations; Colorectal Neoplasms; Drug Resistance; Enzyme Inhibitors; Gene Rearrangement; Humans; Phosphonoacetic Acid; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Assessment of the allosteric mechanism of aspartate transcarbamoylase based on the crystalline structure of the unregulated catalytic subunit.
Topics: Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Catalysis; Crystallography, X-Ray; Enzyme Inhibitors; Escherichia coli; Models, Molecular; Phosphonoacetic Acid; Protein Conformation; Protein Structure, Secondary | 1999 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Colorectal Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Interferon-alpha; Leucovorin; Liver Neoplasms; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasms; Phosphonoacetic Acid; Regional Blood Flow; Stomach Neoplasms; Tomography, Emission-Computed | 1999 |
Micronuclei formation with chromosome breaks and gene amplification caused by Vpr, an accessory gene of human immunodeficiency virus.
Topics: Aneuploidy; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Cycle; Dihydroorotase; Fibrosarcoma; G2 Phase; Gene Amplification; Gene Products, vpr; Genes, vpr; HIV-1; Humans; In Situ Hybridization; In Situ Nick-End Labeling; Micronuclei, Chromosome-Defective; Multienzyme Complexes; Phosphonoacetic Acid; Tumor Cells, Cultured; vpr Gene Products, Human Immunodeficiency Virus | 1999 |
The 80s loop of the catalytic chain of Escherichia coli aspartate transcarbamoylase is critical for catalysis and homotropic cooperativity.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Catalytic Domain; Escherichia coli; Kinetics; Models, Molecular; Mutagenesis, Site-Directed; Phosphonoacetic Acid; Scattering, Radiation | 1999 |
Half of Saccharomyces cerevisiae carbamoyl phosphate synthetase produces and channels carbamoyl phosphate to the fused aspartate transcarbamoylase domain.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Carbamyl Phosphate; Feedback; Multienzyme Complexes; Phosphonoacetic Acid; Phosphotransferases (Carboxyl Group Acceptor); Plasmids; Pyrimidines; Saccharomyces cerevisiae; Uridine Triphosphate | 1999 |
Upregulation of CHOP-10 (gadd153) expression in the mouse blastocyst as a response to stress.
Topics: Actins; Animals; Apoptosis; Arsenates; Aspartic Acid; Blastocyst; Blotting, Northern; CCAAT-Enhancer-Binding Proteins; DNA-Binding Proteins; Enzyme Inhibitors; Female; Methyl Methanesulfonate; Mice; Mice, Inbred C57BL; Phosphonoacetic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stress, Physiological; Transcription Factor CHOP; Transcription Factors; Tumor Cells, Cultured; Tunicamycin; Up-Regulation | 1999 |
Divergent allosteric patterns verify the regulatory paradigm for aspartate transcarbamylase.
Topics: Allosteric Regulation; Allosteric Site; Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Base Sequence; Catalytic Domain; Conserved Sequence; Enterobacteriaceae; Enzyme Activation; Escherichia coli; Escherichia coli Proteins; Genes, Bacterial; Holoenzymes; Kinetics; Models, Biological; Molecular Sequence Data; Molecular Weight; Nucleotides; Operon; Phosphonoacetic Acid; Recombinant Fusion Proteins; Sequence Alignment | 1999 |
Substitutions in the aspartate transcarbamoylase domain of hamster CAD disrupt oligomeric structure.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Carbamyl Phosphate; CHO Cells; Cricetinae; Dihydroorotase; Encephalomyocarditis virus; Molecular Structure; Multienzyme Complexes; Mutagenesis, Site-Directed; Phosphonoacetic Acid; Plasmids; Protein Conformation; Transfection | 2000 |
Insights into the mechanisms of catalysis and heterotropic regulation of Escherichia coli aspartate transcarbamoylase based upon a structure of the enzyme complexed with the bisubstrate analogue N-phosphonacetyl-L-aspartate at 2.1 A.
Topics: Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Catalysis; Catalytic Domain; Crystallography, X-Ray; Escherichia coli; Models, Molecular; Phosphonoacetic Acid; Protein Conformation; Static Electricity; Substrate Specificity | 1999 |
Uracil misincorporation, DNA strand breaks, and gene amplification are associated with tumorigenic cell transformation in folate deficient/repleted Chinese hamster ovary cells.
Topics: Animals; Aspartic Acid; Cell Death; Cell Division; Cell Transformation, Neoplastic; CHO Cells; Cricetinae; DNA Damage; Folic Acid Deficiency; Gene Amplification; Mice; Mice, Inbred BALB C; Phosphonoacetic Acid; Thymine Nucleotides; Uracil | 1999 |
Late onset of CAD gene amplification in unamplified PALA resistant Chinese hamster mutants.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); CHO Cells; Cricetinae; Dihydroorotase; Drug Resistance, Neoplasm; Gene Amplification; Gene Dosage; Multienzyme Complexes; Mutation; Phosphonoacetic Acid | 2000 |
[Effect of inactivating the p33ING1 tumor suppressor on the function of cell cycle "checkpoints" and genome stability].
Topics: Animals; Aspartic Acid; Cell Cycle; Cell Cycle Proteins; Demecolcine; DNA Replication; DNA-Binding Proteins; Ethyl Methanesulfonate; Genes, Tumor Suppressor; Genome; Humans; Inhibitor of Growth Protein 1; Intracellular Signaling Peptides and Proteins; Nuclear Proteins; Phosphonoacetic Acid; Polyploidy; Proteins; Rats; Sister Chromatid Exchange; Transduction, Genetic; Tumor Suppressor Proteins | 2000 |
Binding of bisubstrate analog promotes large structural changes in the unregulated catalytic trimer of aspartate transcarbamoylase: implications for allosteric regulation.
Topics: Allosteric Regulation; Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Crystallography, X-Ray; Enzyme Inhibitors; Escherichia coli; Kinetics; Macromolecular Substances; Molecular Sequence Data; Phosphonoacetic Acid; Protein Conformation; Protein Structure, Quaternary | 2000 |
In vitro cytotoxic effect of N-(phosphonacetyl)-L-aspartic acid in liposome against C-26 murine colon carcinoma.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Carriers; Liposomes; Mice; Particle Size; Phosphonoacetic Acid; Tumor Cells, Cultured | 2000 |
A mutant of Sindbis virus that is resistant to pyrazofurin encodes an altered RNA polymerase.
Topics: Adenosine; Aedes; Amides; Amino Acid Substitution; Animals; Aspartic Acid; Binding Sites; Cells, Cultured; Chick Embryo; DNA-Directed RNA Polymerases; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fibroblasts; Guanosine; Models, Molecular; Mutation; Phenotype; Phosphonoacetic Acid; Protein Structure, Tertiary; Pyrazoles; Recombination, Genetic; Ribonucleosides; Ribose; Sindbis Virus; Virus Replication | 2000 |
The contribution of individual interchain interactions to the stabilization of the T and R states of Escherichia coli aspartate transcarbamoylase.
Topics: Adenosine Triphosphate; Allosteric Regulation; Aspartate Carbamoyltransferase; Aspartic Acid; Catalytic Domain; Cytidine Triphosphate; Escherichia coli; Holoenzymes; Kinetics; Phosphonoacetic Acid | 2000 |
Gene amplification and microsatellite instability induced in tumorigenic human bronchial epithelial cells by alpha particles and heavy ions.
Topics: Alpha Particles; Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Bronchi; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Transformation, Neoplastic; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 3; Dihydroorotase; Drug Resistance, Neoplasm; Epithelial Cells; Gene Amplification; Heavy Ions; Humans; Iron; Lung Neoplasms; Mice; Mice, Nude; Microsatellite Repeats; Multienzyme Complexes; Neoplasm Proteins; Neoplasms, Radiation-Induced; Phosphonoacetic Acid; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Differential gene expression in p53-mediated G(1) arrest of human fibroblasts after gamma-irradiation or N-phosphoacetyl-L-aspartate treatment.
Topics: Aspartic Acid; Carrier Proteins; Cell Adhesion Molecules; Cell Cycle; Cell Line; Chromosome Mapping; Chromosomes, Human, Pair 7; Expressed Sequence Tags; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins; Fibroblasts; G1 Phase; Gamma Rays; Gene Expression Regulation; Growth Inhibitors; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Metaphase; Phosphonoacetic Acid; Skin; Tumor Suppressor Protein p53 | 2000 |
Gene amplification in fibroblasts from ataxia telangiectasia (AT) patients and in X-ray hypersensitive AT-like Chinese hamster mutants.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Ataxia Telangiectasia; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Cricetinae; Cricetulus; Dihydroorotase; Drug Resistance, Neoplasm; Fibroblasts; Gene Amplification; Genetic Complementation Test; Humans; Multienzyme Complexes; Mutation; Phosphonoacetic Acid; Radiation Tolerance; X-Rays | 2001 |
Random circular permutation leading to chain disruption within and near alpha helices in the catalytic chains of aspartate transcarbamoylase: effects on assembly, stability, and function.
Topics: Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Catalytic Domain; Enzyme Activation; Enzyme Stability; Escherichia coli; Escherichia coli Proteins; Holoenzymes; Kinetics; Mutagenesis; Phosphonoacetic Acid; Protein Conformation; Protein Structure, Quaternary; Protein Structure, Secondary | 2001 |
Increased gene amplification in immortal rodent cells deficient for the DNA-dependent protein kinase catalytic subunit.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Catalytic Domain; Cell Line; Cricetinae; Cricetulus; Dihydroorotase; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fibroblasts; Gene Amplification; Mice; Multienzyme Complexes; Phosphonoacetic Acid; Protein Serine-Threonine Kinases | 2001 |
The allosteric activator Mg-ATP modifies the quaternary structure of the R-state of Escherichia coli aspartate transcarbamylase without altering the T<-->R equilibrium.
Topics: Adenosine Triphosphate; Allosteric Regulation; Allosteric Site; Aspartate Carbamoyltransferase; Aspartic Acid; Buffers; Enzyme Activation; Escherichia coli; Holoenzymes; Hydrogen-Ion Concentration; Kinetics; Ligands; Magnesium; Models, Molecular; Phosphonoacetic Acid; Protein Structure, Quaternary; Protein Subunits; Solutions; Thermodynamics; X-Ray Diffraction | 2001 |
Tryptophan residues at subunit interfaces used as fluorescence probes to investigate homotropic and heterotropic regulation of aspartate transcarbamylase.
Topics: Allosteric Regulation; Asparagine; Aspartate Carbamoyltransferase; Aspartic Acid; Escherichia coli; Fluorescent Dyes; Kinetics; Peptide Fragments; Phenylalanine; Phosphonoacetic Acid; Spectrometry, Fluorescence; Substrate Specificity; Titrimetry; Tryptophan; Tyrosine | 2001 |
LDL induced association of anionic liposomes with cells and delivery of contents as shown by the increase in potency of liposome dependent drugs.
Topics: Animals; Anions; Antimetabolites, Antineoplastic; Aspartic Acid; Cell Line; Chlorocebus aethiops; CHO Cells; Cricetinae; Drug Delivery Systems; Lipoproteins, LDL; Liposomes; Methotrexate; Phosphatidylglycerols; Phospholipids; Phosphonoacetic Acid; Receptors, LDL | 2001 |
Genomic instability and tumorigenic induction in immortalized human bronchial epithelial cells by heavy ions.
Topics: Alpha Particles; Animals; Antineoplastic Agents; Aspartic Acid; Bronchi; Cell Fusion; Cell Line, Transformed; Cell Transformation, Neoplastic; Epithelial Cells; Gene Amplification; Genes, Tumor Suppressor; Heavy Ions; Humans; Iron; Linear Energy Transfer; Lung Neoplasms; Mercaptoethylamines; Mice; Mice, Nude; Phosphonoacetic Acid; Radiation-Protective Agents; Tumor Cells, Cultured | 1998 |
High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6.
Topics: Adaptor Proteins, Signal Transducing; Aspartate Carbamoyltransferase; Aspartic Acid; Base Pair Mismatch; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Carrier Proteins; Cell Line; Dihydroorotase; DNA Repair; DNA-Binding Proteins; Drug Resistance; Gene Amplification; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Multienzyme Complexes; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Phosphonoacetic Acid | 2001 |
Revisiting the allosteric mechanism of aspartate transcarbamoylase.
Topics: Allosteric Regulation; Allosteric Site; Aspartate Carbamoyltransferase; Aspartic Acid; Escherichia coli; Phosphonoacetic Acid; Protein Conformation; Thermodynamics; X-Ray Diffraction | 2002 |
N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Aspartic Acid; Chronotherapy; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Phosphonoacetic Acid | 2001 |
Caspase-dependent cleavage of carbamoyl phosphate synthetase II during apoptosis.
Topics: Animals; Apoptosis; Aspartic Acid; Carbamoyl-Phosphate Synthase (Ammonia); Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Caspase 3; Caspases; Cell Line; Drug Resistance; Enzyme Inhibitors; Humans; Interleukin-3; Mice; Peptide Hydrolases; Phosphonoacetic Acid; Protein Structure, Tertiary; Staurosporine; Tumor Cells, Cultured; Uridine Triphosphate | 2002 |
Replacement of Asp-162 by Ala prevents the cooperative transition by the substrates while enhancing the effect of the allosteric activator ATP on E. coli aspartate transcarbamoylase.
Topics: Adenosine Triphosphate; Allosteric Regulation; Amino Acid Substitution; Aspartate Carbamoyltransferase; Aspartic Acid; Escherichia coli; Phosphonoacetic Acid; Protein Structure, Quaternary; Substrate Specificity; X-Rays | 2002 |
Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.
Topics: Aspartic Acid; Bone Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Enzyme Inhibitors; Gene Amplification; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mutation; Osteosarcoma; Phenotype; Phosphonoacetic Acid; Protein Structure, Tertiary; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Overexpression of the 18 kDa and 22/24 kDa FGF-2 isoforms results in differential drug resistance and amplification potential.
Topics: 3T3 Cells; Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Division; Cell Transformation, Neoplastic; Clone Cells; Diffusion Chambers, Culture; Dihydroorotase; Drug Resistance; Enzyme Inhibitors; Fibroblast Growth Factor 2; Fibroblasts; Gene Amplification; Gene Expression; Immunoblotting; Mice; Molecular Weight; Phosphonoacetic Acid; Protein Isoforms; Transfection | 2002 |
[S-phase arrest associated apoptosis leads to diversities of drug resistance and mutation rate in human breast cancer cells].
Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Breast Neoplasms; Drug Resistance, Neoplasm; Humans; Phosphonoacetic Acid; Point Mutation; S Phase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Genomic instability driven by the human T-cell leukemia virus type I (HTLV-I) oncoprotein, Tax.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line, Transformed; Dihydroorotase; Gene Amplification; Gene Products, tax; Genetic Techniques; Human T-lymphotropic virus 1; Multienzyme Complexes; Phosphonoacetic Acid; Rats | 2002 |
The role of intersubunit interactions for the stabilization of the T state of Escherichia coli aspartate transcarbamoylase.
Topics: Adenosine Triphosphate; Alanine; Allosteric Site; Aspartate Carbamoyltransferase; Aspartic Acid; Catalytic Domain; Chromatography, Ion Exchange; Cytidine Triphosphate; Enzyme Inhibitors; Escherichia coli; Ligands; Lysine; Models, Molecular; Mutation; Phosphonoacetic Acid; Protein Binding; Protein Structure, Tertiary; Scattering, Radiation; X-Rays | 2002 |
[Embryonal stem cells do not undergo cell cycle arrest upon exposure to damaging factors].
Topics: Acetylcysteine; Animals; Aspartic Acid; Cell Cycle; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Doxorubicin; Embryo, Mammalian; Mice; Nocodazole; Phosphonoacetic Acid; Stem Cells; Tumor Cells, Cultured | 2002 |
Gamma-ray and hydrogen peroxide induction of gene amplification in hamster cells deficient in DNA double strand break repair.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Cell Line; Chromosome Aberrations; Cricetinae; Cricetulus; DNA; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gamma Rays; Gene Amplification; Hydrogen Peroxide; Multienzyme Complexes; Oxidants; Phosphonoacetic Acid; Protein Serine-Threonine Kinases | 2002 |
Aspartate transcarbamylase from the hyperthermophilic archaeon Pyrococcus abyssi: thermostability and 1.8A resolution crystal structure of the catalytic subunit complexed with the bisubstrate analogue N-phosphonacetyl-L-aspartate.
Topics: Amino Acid Sequence; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Enzyme Stability; Escherichia coli; Holoenzymes; Hydrogen Bonding; Kinetics; Models, Molecular; Molecular Sequence Data; Phosphonoacetic Acid; Protein Structure, Tertiary; Protein Subunits; Pyrococcus; Temperature; Thermodynamics | 2003 |
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Interferon alpha-2; Interferon-alpha; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphonoacetic Acid; Prognosis; Recombinant Proteins; Retrospective Studies; Survival Rate; Thymidylate Synthase; Treatment Outcome | 2003 |
Synthesis and biological evaluation of S-acyl-3-thiopropyl prodrugs of N-phosphonoacetyl-L-aspartate (PALA).
Topics: Antineoplastic Agents; Aspartic Acid; Cell Division; Cell Line, Tumor; Humans; Inhibitory Concentration 50; Phosphonoacetic Acid; Prodrugs; Structure-Activity Relationship; Sulfhydryl Compounds | 2003 |
Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Brain Neoplasms; Bromodeoxyuridine; Cell Line, Tumor; Combined Modality Therapy; Drug Combinations; Drug Implants; Fluorouracil; Glioma; Immunologic Factors; Methotrexate; Phosphonoacetic Acid; Radiation-Sensitizing Agents; Rats | 2004 |
Aspartate transcarbamylase (ATCase) of Escherichia coli: a new crystalline R-state bound to PALA, or to product analogues citrate and phosphate.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Citrates; Crystallography, X-Ray; Escherichia coli Proteins; Holoenzymes; Models, Molecular; Phosphates; Phosphonoacetic Acid; Protein Conformation | 2004 |
Genomic instability in Gadd45a-/- cells is coupled with S-phase checkpoint defects.
Topics: Aneuploidy; Animals; Aspartic Acid; Cell Cycle Proteins; Cell Line; Centrosome; Chromosome Segregation; Cyclin-Dependent Kinase Inhibitor p21; DNA; DNA Replication; G1 Phase; Gene Amplification; Gene Deletion; Gene Expression Regulation; Genes, cdc; Genes, p53; Genomic Instability; Hydroxyurea; Mice; Nuclear Proteins; Phosphonoacetic Acid; S Phase | 2005 |
A single amino acid substitution in the active site of Escherichia coli aspartate transcarbamoylase prevents the allosteric transition.
Topics: Allosteric Regulation; Amino Acid Substitution; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Crystallography, X-Ray; Escherichia coli; Glutamine; Models, Molecular; Phosphonoacetic Acid; Protein Structure, Quaternary; Protein Subunits; Static Electricity; Structure-Activity Relationship | 2005 |
Efficient synthesis of fluorothiosparfosic acid analogues with potential antitumoral activity.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Leukemia L1210; Phosphonoacetic Acid; Thioacetamide | 2005 |
Severe cytochrome c oxidase inhibition in vivo does not induce a pyrimidine deficiency; neuroprotective action of oral uridine prodrug PN401 requires supraphysiological levels of uridine.
Topics: Acetates; Animals; Apoptosis; Aspartic Acid; Azides; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Electron Transport; Electron Transport Complex IV; Enzyme Inhibitors; Fibroblasts; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred C57BL; Mitochondria; Neuroprotective Agents; Phosphonoacetic Acid; Prodrugs; Pyrimidines; Uridine | 2005 |
Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.
Topics: Acetates; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunologic Factors; Leucovorin; Liver Neoplasms; Male; Methotrexate; Middle Aged; Phosphonoacetic Acid; Remission Induction; Uridine; Vitamin B Complex | 2006 |
Inhibition of gene amplification in telomerase deficient immortalized mouse embryonic fibroblasts.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Chromosome Mapping; Dihydroorotase; Drug Resistance; Embryo, Mammalian; Fibroblasts; Gene Amplification; In Situ Hybridization, Fluorescence; Mice; Mice, Knockout; Phosphonoacetic Acid; Telomerase | 2007 |
N-phosphonacetyl-L-isoasparagine a potent and specific inhibitor of Escherichia coli aspartate transcarbamoylase.
Topics: Asparagine; Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Crystallography, X-Ray; Escherichia coli; Hydrogen Bonding; Kinetics; Models, Molecular; Molecular Structure; Organophosphonates; Phosphonoacetic Acid | 2006 |
Picosecond dynamics of T and R forms of aspartate transcarbamylase: a neutron scattering study.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Elasticity; Enzyme Activation; Escherichia coli; Neutrons; Phosphonoacetic Acid; Protein Structure, Quaternary; Scattering, Radiation | 2006 |
Enriching suicide gene bearing tumor cells for an increased bystander effect.
Topics: Animals; Aspartic Acid; Bystander Effect; Cell Line, Tumor; Cytosine Deaminase; Female; Flucytosine; Genetic Therapy; Mice; Pentosyltransferases; Phosphonoacetic Acid; Plasmids | 2007 |
Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors.
Topics: Apoptosis; Aspartic Acid; Cell Line; Cytokines; DNA; Epithelial Cells; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 15; Humans; Phosphonoacetic Acid; S Phase; Signal Transduction; Tumor Suppressor Protein p53 | 2006 |
Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.
Topics: Amides; Aspartate Carbamoyltransferase; Aspartic Acid; Catalytic Domain; Chemistry, Pharmaceutical; Drug Design; Escherichia coli; Kinetics; Models, Chemical; Molecular Conformation; Molecular Structure; Phosphonoacetic Acid; Structure-Activity Relationship; Substrate Specificity | 2007 |
Autophagy suppresses tumor progression by limiting chromosomal instability.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Aspartic Acid; Autophagy; Autophagy-Related Protein 5; Beclin-1; Blotting, Western; Cells, Cultured; Centrosome; Chromosomal Instability; Chromosome Aberrations; Disease Progression; DNA Damage; Epithelial Cells; Fluorescent Antibody Technique; Kidney; Loss of Heterozygosity; Metabolism; Mice; Mice, Knockout; Microtubule-Associated Proteins; Neoplasms; Phosphonoacetic Acid; Ploidies; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Signal Transduction | 2007 |
DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation.
Topics: Aspartic Acid; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line; Checkpoint Kinase 1; DNA; DNA Damage; DNA-Binding Proteins; Humans; Models, Biological; Nucleotides; Phosphonoacetic Acid; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Pyrimidines; S Phase; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2008 |
Submicromolar phosphinic inhibitors of Escherichia coli aspartate transcarbamoylase.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding, Competitive; Catalysis; Chemistry, Pharmaceutical; Colorimetry; Drug Design; Enzyme Inhibitors; Escherichia coli; Escherichia coli Proteins; Kinetics; Models, Chemical; Phosphonoacetic Acid; Phosphorus; Protein Conformation | 2009 |
Synthesis and in vitro evaluation of aspartate transcarbamoylase inhibitors.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Binding Sites; Biocatalysis; Drug Evaluation, Preclinical; Enzyme Inhibitors; Enzyme Stability; Escherichia coli; Models, Chemical; Phosphonoacetic Acid; Structure-Activity Relationship | 2009 |
Targeting eradication of malignant cells derived from human bone marrow mesenchymal stromal cells.
Topics: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Adult; Animals; Antigens, CD; Antimetabolites; Aspartic Acid; Bone Marrow Cells; Cell Differentiation; Cell Survival; Cell Transformation, Neoplastic; Cytosine Deaminase; Escherichia coli Proteins; Flucytosine; Gene Expression; Genes, Reporter; Genetic Vectors; Green Fluorescent Proteins; Humans; Kruppel-Like Transcription Factors; Lentivirus; Luciferases; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Phosphonoacetic Acid; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Response Elements; Stromal Cells; Telomerase; Transduction, Genetic; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays; Young Adult | 2010 |
N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Aspartic Acid; Bcl-2-Like Protein 11; Cells, Cultured; DNA-Binding Proteins; Drug Evaluation, Preclinical; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasms; Nuclear Proteins; Phosphonoacetic Acid; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation | 2013 |
Heat induces gene amplification in cancer cells.
Topics: Acid Anhydride Hydrolases; Acylphosphatase; Aspartate Carbamoyltransferase; Aspartic Acid; Dihydroorotase; DNA Breaks, Double-Stranded; Gene Amplification; Gene Expression Regulation, Neoplastic; HCT116 Cells; Hot Temperature; Humans; Hyperthermia, Induced; Neoplasms; Phosphonoacetic Acid | 2012 |
Expression, purification, crystallization and preliminary X-ray diffraction analysis of the aspartate transcarbamoylase domain of human CAD.
Topics: Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Crystallization; Crystallography, X-Ray; Dihydroorotase; Enzyme Inhibitors; Escherichia coli; Gene Expression; Models, Molecular; Phosphonoacetic Acid; Protein Multimerization; Protein Structure, Tertiary; Recombinant Proteins; Synchrotrons | 2013 |
Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Aspartic Acid; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin A; Cyclin-Dependent Kinase 2; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mice; Mice, Nude; Phosphonoacetic Acid; Up-Regulation | 2015 |
Structure and Functional Characterization of Human Aspartate Transcarbamoylase, the Target of the Anti-tumoral Drug PALA.
Topics: Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Catalytic Domain; Enzyme Inhibitors; Humans; Phosphonoacetic Acid | 2016 |
Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Topics: Amides; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Biphenyl Compounds; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Carcinoma, Squamous Cell; Cell Line, Tumor; Dihydroorotate Dehydrogenase; Head and Neck Neoplasms; Humans; Isoxazoles; Naphthoquinones; Orotate Phosphoribosyltransferase; Oxidoreductases Acting on CH-CH Group Donors; Phosphonoacetic Acid; Purine Nucleotides; Pyrazoles; Pyrimidine Nucleotides; Ribonucleosides; Ribose | 2018 |
Pyrimidine synthesis inhibition enhances cutaneous defenses against antibiotic resistant bacteria through activation of NOD2 signaling.
Topics: Animals; Aspartic Acid; Bacteria; Dermis; Drug Resistance, Multiple, Bacterial; HEK293 Cells; Humans; Immunity, Innate; Nod2 Signaling Adaptor Protein; Phosphonoacetic Acid; Pyrimidines; Signal Transduction; Skin Diseases, Bacterial; Swine | 2018 |
Allostery and cooperativity in multimeric proteins: bond-to-bond propensities in ATCase.
Topics: Adenosine Triphosphate; Allosteric Regulation; Allosteric Site; Aspartate Carbamoyltransferase; Aspartic Acid; Catalytic Domain; Cytidine Triphosphate; Enzyme Stability; Models, Molecular; Phosphonoacetic Acid; Protein Multimerization; Protein Subunits; Substrate Specificity | 2018 |
Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.
Topics: Antiviral Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Line; Dihydroorotase; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Fulvestrant; Gene Silencing; Hepatitis D, Chronic; Hepatitis Delta Virus; Hepatocytes; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin Resistance; Life Cycle Stages; Loss of Function Mutation; Phosphonoacetic Acid; Pyrimidines; RNA Interference; RNA, Small Interfering; RNA, Viral; Signal Transduction; Virus Replication | 2020 |